Deuterated imidazoxazol and use method thereof
The deuterated imidazoxin compound improved the drug's metabolic properties, solved the problem of unstable metabolic rate of imidazoxin in vivo, and achieved higher bioavailability and longer residence time in vivo.
Patent Information
- Application Number
- CN202380026543.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-16
- Filing Date
- 2023-02-16
- Publication Date
- 2024-11-29
AI Technical Summary
The metabolic rate of imidazolidinedion in vivo is unstable, and the formation of its metabolites is difficult to control, affecting its pharmacokinetic properties.
By replacing the hydrogen atoms in imidazolidinedion with deuterium atoms, deuterated imidazolidinedion compounds are formed, which slow down the metabolic process and improve the metabolic properties of the drug.
It improves the stability and bioavailability of deuterated imidazolidinedion compounds in vivo, reduces the formation of unnecessary metabolites, and prolongs their residence time in the systemic circulation.
Smart Images

Figure CN119053573A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 320,342, filed on March 16, 2022, and U.S. Provisional Application No. 63 / 310,686, filed on February 16, 2022, the contents of each of which are incorporated by reference in their entirety. Background Art
[0003] Idazoxan has been evaluated as a selective α2 adrenergic receptor antagonist and imidazoline receptor antagonist, but is converted to one or more metabolites. In addition, only about 27-28% of idazoxan enters the systemic circulation, from which it is eliminated through the urine. The major metabolites of idazoxan include hydroxylation of the benzene ring at the 6- and / or 7-positions and their glucuronic acid conjugates. Sulfate conjugates of 7-OH metabolites can also be produced. Only small amounts of 5-OH compounds have been detected, and there is no evidence that 8-OH compounds are metabolites of idazoxan. In terms of the imidazoline ring, the major metabolite is produced by ring opening. There are many other minor metabolites that have not yet been identified. The metabolic scheme of idazoxan is as follows:
[0004]
[0005] The present disclosure provides deuterated idazoxan analogs that are intended to improve the pharmacokinetic and metabolic properties of idazoxan. In fact, a potentially attractive strategy for improving the metabolic properties of drugs is deuterium modification. In this approach, one attempts to slow down the metabolism of a drug or reduce the formation of unwanted metabolites by replacing one or more hydrogen atoms with deuterium atoms. Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Deuterium forms a stronger bond with carbon than hydrogen.
[0006] Over the past 35 years, deuterium replacement has been reported to affect the metabolic rate of a very small percentage of approved drugs (see, e.g., Blake, MI, et al., J Pharm Sci, 1975, 64:367-91; Foster, AB, Adv Drug Res 1985, 14:1-40 ("Foster"); Kushner, DJ, et al., Can J Physiol Pharmacol 1999, 79-88; Fisher, MB, et al., Curr Opin Drug Discov Devel, 2006, 9:101-09 ("Fisher")). The results vary and are difficult to predict. For some compounds, deuteration results in decreased metabolic clearance in vivo. For other compounds, metabolism is unchanged. Still other compounds show increased metabolic clearance. The variability of deuteration effects has also led experts to question or dismiss deuteration modification as a viable drug design strategy to inhibit adverse metabolism (see Foster, p. 35 and Fisher, p. 101) Summary of the invention
[0007] In one aspect, the present application relates to compounds of formula (I):
[0008]
[0009] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0010] In another aspect, the present application relates to compounds of formula (II) or formula (III):
[0011]
[0012] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0013] In another aspect, the present application relates to compounds of formula (II-A) or formula (III-A):
[0014]
[0015] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0016] In another aspect, the present application relates to compounds of formula (IA):
[0017]
[0018] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0019] In another aspect, the present application relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof and a pharmaceutically acceptable carrier.
[0020] Another aspect of the present application relates to a method for treating a nervous system disorder, comprising administering an effective amount of the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, or the pharmaceutical composition of the present application to a subject in need thereof.
[0021] Another aspect of the present application relates to a method for treating or preventing a disease, wherein the disease is caused by a nervous system disorder. The method comprises administering an effective amount of a compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, or a pharmaceutical composition of the present application to a subject in need thereof.
[0022] Another aspect of the present application relates to a kit comprising the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, or the pharmaceutical composition of the present application.
[0023] Another aspect of the present application relates to the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, or the pharmaceutical composition of the present application, which is used for the manufacture of a medicament for treating a nervous system disorder.
[0024] The details of the present disclosure are listed in the following attached description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, illustrative methods and materials are now described. In the event of a conflict, this specification (including definitions) shall prevail. In addition, the materials, methods and examples are only illustrative and are not intended to be restrictive. Other features, objects and advantages of the present disclosure will be apparent from the specification and claims. In the specification and the appended claims, the singular form also includes the plural form, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present disclosure belongs, which are generally understood.
[0025] The contents of all documents cited throughout this application (including references, issued patents, published patent applications, and co-pending patent applications) are hereby expressly incorporated herein by reference in their entirety. The references cited herein are not admitted to be prior art to this application. DETAILED DESCRIPTION
[0026] In one aspect, the present application relates to compounds of formula (I):
[0027]
[0028] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0029] In another aspect, the present application relates to compounds of formula (II) or formula (III):
[0030]
[0031] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0032] In another aspect, the present application relates to compounds of formula (II-A) or formula (III-A):
[0033]
[0034] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0035] In another aspect, the present application relates to compounds of formula (IA):
[0036]
[0037] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0038] In another aspect, the present application relates to compounds of formula (IAR) or (1-AS):
[0039]
[0040] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
[0041] In one aspect, the present application relates to compounds of formula (IV), formula (IV-S) or formula (IV-R):
[0042]
[0043] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium.
[0044] In one aspect, the present application relates to compounds of formula (V), formula (VS) or formula (VR):
[0045]
[0046] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 5 , R 6 , R 7 and R 8 At least one of each is independently selected from hydrogen and deuterium.
[0047] In one aspect, the present application relates to compounds of formula (VI), formula (VI-S) or formula (VI-R):
[0048]
[0049] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 , R 2’ , R 5 and R 8 are each independently selected from hydrogen and deuterium.
[0050] In one aspect, the present application relates to compounds of formula (VII), formula (VII-S) or formula (VII-R):
[0051]
[0052] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 and R 2’ are each independently selected from hydrogen and deuterium.
[0053] In one aspect, the present application relates to compounds of formula (VIII), formula (VIII-S) or formula (VIII-R):
[0054]
[0055] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2, R 2’ , R 6 and R 7 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1’ , R 2 , R 2’ , R 6 and R 7 At least one of each is independently selected from hydrogen and deuterium.
[0056] In one aspect, the present application relates to compounds of formula (IX), formula (IX-S) or formula (IX-R):
[0057]
[0058] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 , R 2’ and R 6 are each independently selected from hydrogen and deuterium.
[0059] In one aspect, the present application relates to compounds of formula (X), formula (XS) or formula (XR):
[0060]
[0061] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 , R 2’ and R 7 are each independently selected from hydrogen and deuterium.
[0062] In one aspect, the present application relates to compounds of formula (XI), formula (XI-S) or formula (XI-R):
[0063]
[0064] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 and R 2’ are each independently selected from hydrogen and deuterium.
[0065] In one aspect, the present application relates to compounds of formula (XII), formula (XII-S) or formula (XII-R):
[0066]
[0067] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1’ , R 2 and R 2’ are each independently selected from hydrogen and deuterium.
[0068] In one aspect, the present application relates to a compound of Formula (I), (II), (III), (II-A), (III-A), (IA), (IAR), (IAS), (IV), (IV-S), (IV-R), (V), (VS), (VR), (VI), (VI-S), (VI-R), (VII), (VII-S), (VII-R), (VIII), (VIII-S), (VIII-R), (IX), (IX-S), (IX-R), (X), (XS), (XR), (XI), (XI-S), (XI-R), (XII), (XII-S) or (XII-R), or a pharmaceutically acceptable salt thereof. In one aspect, the present application relates to compounds of Formula (I), (II), (III), (II-A), (III-A), (IA), (IAR), (IAS), (IV), (IV-S), (IV-R), (V), (VS), (VR), (VI), (VI-S), (VI-R), (VII), (VII-S), (VII-R), (VIII), (VIII-S), (VIII-R), (IX), (IX-S), (IX-R), (X), (XS), (XR), (XI), (XI-S), (XI-R), (XII), (XII-S) or (XII-R).
[0069] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 One of them is deuterium.
[0070] In some embodiments, R 1 , R 1 '、R2 , R 2 '、R 5 , R 6 , R 7 and R 8 One of them is deuterium.
[0071] In some embodiments, R 1 For deuterium.
[0072] In some embodiments, R 1 'For deuterium.
[0073] In some embodiments, R 2 For deuterium.
[0074] In some embodiments, R 2 'For deuterium.
[0075] In some embodiments, R 3 For deuterium.
[0076] In some embodiments, R 4 For deuterium.
[0077] In some embodiments, R 4 'For deuterium.
[0078] In some embodiments, R 5 For deuterium.
[0079] In some embodiments, R 6 For deuterium.
[0080] In some embodiments, R 7 For deuterium.
[0081] In some embodiments, R 8 For deuterium.
[0082] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Two of them are deuterium.
[0083] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6, R 7 and R 8 Two of them are deuterium.
[0084] In some embodiments, R 1 is deuterium and R 1 'For deuterium.
[0085] In some embodiments, R 2 is deuterium and R 2 'For deuterium.
[0086] In some embodiments, R 4 is deuterium and R 4 'For deuterium.
[0087] In some embodiments, R 5 is deuterium and R 6 For deuterium.
[0088] In some embodiments, R 5 is deuterium and R 7 For deuterium.
[0089] In some embodiments, R 5 is deuterium and R 8 For deuterium.
[0090] In some embodiments, R 6 is deuterium and R 7 For deuterium.
[0091] In some embodiments, R 6 is deuterium and R 8 For deuterium.
[0092] In some embodiments, R 7 is deuterium and R 8 For deuterium.
[0093] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Three of them are deuterium.
[0094] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R6 , R 7 and R 8 Three of them are deuterium.
[0095] In some embodiments, R 1 , R 1 ' and R 5 Each is deuterium.
[0096] In some embodiments, R 1 , R 1 ' and R 6 Each is deuterium.
[0097] In some embodiments, R 1 , R 1 ' and R 7 Each is deuterium.
[0098] In some embodiments, R 1 , R 1 ' and R 8 Each is deuterium.
[0099] In some embodiments, R 2 , R 2 ' and R 5 Each is deuterium.
[0100] In some embodiments, R 2 , R 2 ' and R 6 Each is deuterium.
[0101] In some embodiments, R 2 , R 2 ' and R 7 Each is deuterium.
[0102] In some embodiments, R 2 , R 2 ' and R 8 Each is deuterium.
[0103] In some embodiments, R 1 , R 5 and R 6 Each is deuterium.
[0104] In some embodiments, R 1 , R 5 and R 7 Each is deuterium.
[0105] In some embodiments, R 1 , R 5 and R 8 Each is deuterium.
[0106] In some embodiments, R 1 , R 6 and R 7 Each is deuterium.
[0107] In some embodiments, R 1 , R 6 and R 8 Each is deuterium.
[0108] In some embodiments, R 1 , R 7 and R 8 Each is deuterium.
[0109] In some embodiments, R 1 '、R 5 and R 6 Each is deuterium.
[0110] In some embodiments, R 1 '、R 5 and R 7 Each is deuterium.
[0111] In some embodiments, R 1 '、R 5 and R 8 Each is deuterium.
[0112] In some embodiments, R 1 '、R 6 and R 7 Each is deuterium.
[0113] In some embodiments, R 1 '、R 6 and R 8 Each is deuterium.
[0114] In some embodiments, R 1 '、R 7 and R 8 Each is deuterium.
[0115] In some embodiments, R 2 , R 5 and R 6 Each is deuterium.
[0116] In some embodiments, R 2 , R 5 and R 7 Each is deuterium.
[0117] In some embodiments, R 2 , R 5 and R 8 Each is deuterium.
[0118] In some embodiments, R 2 , R 6 and R 7 Each is deuterium.
[0119] In some embodiments, R 2 , R 6 and R 8 Each is deuterium.
[0120] In some embodiments, R 2 , R 7 and R 8 Each is deuterium.
[0121] In some embodiments, R 2 '、R 5 and R 6 Each is deuterium.
[0122] In some embodiments, R 2 '、R 5 and R 7 Each is deuterium.
[0123] In some embodiments, R 2 '、R 5 and R 8 Each is deuterium.
[0124] In some embodiments, R 2 '、R 6 and R 7 Each is deuterium.
[0125] In some embodiments, R 2 '、R 6 and R 8 Each is deuterium.
[0126] In some embodiments, R 2 '、R 7 and R 8 Each is deuterium.
[0127] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Four of them are deuterium.
[0128] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Four of them are deuterium.
[0129] In some embodiments, R 1 , R 1 '、R 5 and R 6 Each is deuterium.
[0130] In some embodiments, R 1 , R 1 '、R 5 and R 7 Each is deuterium.
[0131] In some embodiments, R 1 , R 1 '、R 5 and R 8 Each is deuterium.
[0132] In some embodiments, R 1 , R 1 '、R 6 and R 7 Each is deuterium.
[0133] In some embodiments, R 1 , R 1 '、R 6 and R 8 Each is deuterium.
[0134] In some embodiments, R 1 , R 1 '、R 7 and R 8 Each is deuterium.
[0135] In some embodiments, R 2 , R 2 '、R 5 and R 6 Each is deuterium.
[0136] In some embodiments, R 2 , R 2 '、R 5 and R 7 Each is deuterium.
[0137] In some embodiments, R 2 , R 2'、R 5 and R 8 Each is deuterium.
[0138] In some embodiments, R 2 , R 2 '、R 6 and R 7 Each is deuterium.
[0139] In some embodiments, R 2 , R 2 '、R 6 and R 8 Each is deuterium.
[0140] In some embodiments, R 2 , R 2 '、R 7 and R 8 Each is deuterium.
[0141] In some embodiments, R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0142] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Five of them are deuterium.
[0143] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Five of them are deuterium.
[0144] In some embodiments, R 1 , R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0145] In some embodiments, R 1 '、R 5 , R 6, R 7 and R 8 Each is deuterium.
[0146] In some embodiments, R 2 , R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0147] In some embodiments, R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0148] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Six of them are deuterium.
[0149] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Six of them are deuterium.
[0150] In some embodiments, R 1 , R 1 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0151] In some embodiments, R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0152] In some embodiments, R 1 , R 2 , R 5 , R 6 , R7 and R 8 Each is deuterium.
[0153] In some embodiments, R 1 , R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0154] In some embodiments, R 1 '、R 2 , R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0155] In some embodiments, R 1 '、R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0156] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Seven of them are deuterium.
[0157] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Seven of them are deuterium.
[0158] In some embodiments, R 1 , R 1 '、R 2 , R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0159] In some embodiments, R 1 , R 1'、R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0160] In some embodiments, R 1 , R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0161] In some embodiments, R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0162] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Eight of them are deuterium.
[0163] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Eight of them are deuterium.
[0164] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 Each is deuterium.
[0165] In some embodiments, R 1 , R 1 '、R 2 , R 2'、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least two of them are deuterium.
[0166] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least three of them are deuterium.
[0167] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least four of them are deuterium.
[0168] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least five of them are deuterium.
[0169] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least six of them are deuterium.
[0170] In some embodiments, R1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least seven of them are deuterium.
[0171] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least eight of them are deuterium.
[0172] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least nine of them are deuterium.
[0173] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least ten of them are deuterium.
[0174] In some embodiments, R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R8 All deuterium.
[0175] In some embodiments, when one variable is specified as deuterium, the remaining variables are hydrogen. In some embodiments, when one variable is specified as deuterium, the remaining variables are hydrogen or deuterium.
[0176] Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen", the position is understood to have hydrogen or an isotope thereof, such as deuterium (d, d, D or 2 H) or tritium ( 3 H).
[0177] In some embodiments, each position designated as deuterium has an abundance of deuterium at that position that is significantly greater than the natural abundance of deuterium, which is approximately 0.015%.
[0178] In some embodiments, each position designated as deuterium has at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% deuterium incorporation.
[0179] In some embodiments, each position designated as deuterium has at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% deuterium incorporation.
[0180] In some embodiments, each position specifically designated as deuterium has at least about 90% deuterium incorporation. In some embodiments, each position specifically designated as deuterium has at least about 95% deuterium incorporation. In some embodiments, each position specifically designated as deuterium has at least about 97% deuterium incorporation.
[0181] Any of the embodiments herein apply, where applicable, to Formula (I), (II), (III), (III-A), (III-A), (IA), (IAR), (IAS), (IV), (IV-S), (IV-R), (V), (VS), (VR), (VI), (VI-S), (VI-R), (VII), (VII-S), (VII-R), (VIII), (VIII-S), (VIII-R), (IX), (IX-S), (IX-R), (X), (XS), (XR), (XI), (XI-S), (XI-R), (XII), (XII-S), (XII-R), or Table 1. Where applicable, the above for R 1, R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Any of the groups described in any one of the above can be combined with 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 Any combination of groups described in the remainder of the
[0182] The representative compounds of the present application are shown in Table 1.
[0183] Table 1. Compounds of the present disclosure
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195] Some of the aforementioned compounds may contain one or more asymmetric centers, and therefore may exist in various isomeric forms (e.g., stereoisomers and / or diastereomers). Therefore, the compounds of the present application may be in the form of a single enantiomer, diastereomer, or geometric isomer, or may be in the form of a mixture of stereoisomers. In some embodiments, the compounds of the present application are enantiomerically pure compounds. In another embodiment, a mixture of stereoisomers or diastereomers is provided.
[0196] "Isomeric" means compounds that have the same molecular formula but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers", and stereoisomers that are not superimposable mirror images of one another are termed "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture".
[0197] A carbon atom bonded to four non-identical substituents is called a "chiral center."
[0198] "Chiral isomer" means a compound with at least one chiral center. Compounds with more than one chiral center may exist as individual diastereomers or as a mixture of diastereomers (called a "diastereomeric mixture"). When one chiral center is present, stereoisomers may be characterized by the absolute configuration (R or S) of that chiral center (e.g., carbon). Absolute configuration refers to the spatial arrangement of substituents attached to the chiral center. The substituents attached to the chiral center in question are ordered according to the sequence rules of Cahn, Ingold and Prelog (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
[0199] "Geometric isomers" refers to the diastereomers that exist due to hindered rotation about a double bond. These configurations are distinguished in their names by the prefixes "cis" and "trans," or Z and E, which indicate that the groups are located on the same or opposite sides of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
[0200] In addition, the structures and other compounds discussed in this application include all atropisomers thereof. An "atropisomer" is a stereoisomer in which the atoms of the two isomers are arranged differently in space. Atropisomers exist due to restricted rotation of large groups around a central bond that is hindered. Such atropisomers typically exist as a mixture, however, due to recent advances in chromatographic techniques, it is possible to separate a mixture of two atropisomers in selected cases.
[0201] "Tautomer" is one of two or more structural isomers that exist in equilibrium and are easily converted from one isomeric form to another. This conversion results in the migration of the form of hydrogen atoms, accompanied by the conversion of adjacent conjugated double bonds. Tautomers exist as a mixture of sets of tautomers in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization may occur, a chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that can be mutually converted by tautomerization is called tautomerism.
[0202] Among the various types of tautomerism that are possible, two are usually observed. In keto-enol tautomerism, there is a simultaneous movement of electrons and hydrogen atoms. Ring chain tautomerism is caused by the reaction of an aldehyde group (-CHO) in a sugar chain molecule with a hydroxyl group (-OH) in the same molecule, causing it to present a cyclic (ring-shaped) form such as that presented by glucose. Common tautomerism pairs are: keto-enol, amide-nitrile, lactam-lactimide, amide-imidic acid tautomerism in heterocycles (for example, in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine. The compounds of the present application can also be represented in a variety of tautomeric forms, in which case the present application explicitly includes all tautomeric forms of the compounds described herein (for example, alkylation of the ring system may result in alkylation of multiple sites, and the present application explicitly includes all such reaction products).
[0203] In the present application, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers and the like.
[0204] For example, the tautomer represented by the following formula (I) can exist in two forms:
[0205]
[0206] In some embodiments, when one form or the other is described, both tautomers are contemplated.
[0207] In one aspect, an isotopically labeled compound of any formula herein may have one or more additional isotopic atoms introduced into the compound, which may or may not be radioactive (e.g., 3 H. 14 C. 13 C. 18 F. 35 S. 32 P. 125 I and 131 I). Such compounds are useful in drug metabolism studies and diagnostic as well as therapeutic applications.
[0208] The potency can also be measured by IC 50 As determined under substantially similar conditions, a lower IC 50 Compounds with higher IC 50 The compounds with higher values are more effective.
[0209] In some embodiments, the compounds of the present application can be used as therapeutic agents and thus can be used to treat diseases caused by or associated with a nervous system disorder.
[0210] The compounds of the present application are defined herein by their chemical structure and / or chemical name. When a compound is referred to by both a chemical structure and a chemical name, and if the chemical structure and chemical name conflict, the chemical structure determines the identity of the compound.
[0211] The recitation of a list of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of the listed groups. The recitation of an embodiment of a variable herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0212] On the other hand, the application provides a method for synthesizing compounds disclosed herein. The synthesis of compounds of the application can be found in this article and in the following examples. Other embodiments are methods for preparing compounds of any formula described herein using any reaction described herein or a combination thereof. The method may include using one or more intermediates or chemical reagents described herein.
[0213] The present application also provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0214] Another aspect of the present application relates to a kit comprising a compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, or a pharmaceutical composition of the present application. On the other hand, the present application provides a kit comprising a compound capable of treating a nervous system disorder selected from one or more compounds disclosed herein or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally in combination with a second agent, and instructions for use.
[0215] In some embodiments, the compounds of the present application form less one or more metabolites than non-deuterated analogs. In some embodiments, the compounds of the present application form less than about 10%, less than about 20%, less than about 30%, less than about 40%, less than about 50%, less than about 60%, less than about 70%, less than about 80%, less than about 90% or less than about 100% of one or more metabolites compared to non-deuterated analogs. In some embodiments, the compounds of the present application form less than about 10%, less than about 20%, less than about 30%, less than about 40%, less than about 50%, less than about 60%, less than about 70%, less than about 80%, less than about 90% or less than about 100% of 6-OH metabolites compared to non-deuterated analogs. In some embodiments, the compounds of the present application form about 10% less, about 20% less, about 30% less, about 40% less, about 50% less, about 60% less, about 70% less, 80% less, 90% less, or about 100% less 7-OH metabolite compared to the non-deuterated analog.
[0216] In some embodiments, the compounds of the present application have increased bioavailability compared to non-deuterated analogs. In some embodiments, the compounds of the present application have an increased bioavailability of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to non-deuterated analogs.
[0217] In some embodiments, the compounds of the present application are maintained in the systemic circulation for a longer time than non-deuterated analogs. In some embodiments, the compounds of the present application are maintained in the systemic circulation for a longer time than non-deuterated analogs by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100%.
[0218] Method for synthesizing the compound
[0219] The compounds of the present application can be prepared in a variety of ways using standard synthetic methods and procedures known to those skilled in the art or obvious to those skilled in the art according to the teachings herein, using commercially available starting materials, compounds known in the literature, or by easily prepared intermediates. Standard synthetic methods and procedures for preparing organic molecules and functional group transformations and operations can be obtained from relevant scientific literature or from standard textbooks in the field. Although not limited to any one or more sources, the classic texts incorporated herein by reference such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, John Wiley & Sons: New York, 2001; and Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999 are useful and recognized organic synthesis reference textbooks known to those skilled in the art. The following description of the synthetic method is intended to illustrate but not limit the general procedure for preparing the compounds of the present application. These processes generally provide the desired final compound at or near the end of the overall process, but in some cases it may be necessary to further convert the compound into a pharmaceutically acceptable salt, ester or prodrug thereof. Suitable synthetic routes are described in the schemes below.
[0220] Those skilled in the art will recognize whether there is a stereocenter in the compounds disclosed herein. Therefore, the application includes two possible stereoisomers (unless described in the synthesis), and not only includes racemic compounds, but also includes individual enantiomers and / or diastereomers. When the desired compound is as a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by splitting the final product or any convenient intermediate. The splitting of the final product, intermediate or starting material can be achieved by any suitable method known in the art. See, for example, " Stereochemistry of Organic Compounds ", EL Elel, SH Wilen and LN Mander (Wiley-Interscience, 1994).
[0221] The compounds of the present application can be prepared in many ways well known to those skilled in the art of organic synthesis. For example, the compounds of the present application can be synthesized using the methods described below, as well as synthetic methods known in the field of synthetic organic chemistry, or variations thereof known to those skilled in the art. Preferred methods include but are not limited to those described below.
[0222] The compounds of the present application can be synthesized by following the steps outlined in the following schemes, including different orders of assembling intermediates. Starting materials are either commercially available or prepared by methods known in the reported literature or as shown in the following schemes.
[0223] The compounds of the present application can be prepared as pharmaceutically acceptable acid addition salts by reacting the free base form of the compound with a pharmaceutically acceptable inorganic acid or organic acid. Alternatively, the pharmaceutically acceptable base addition salts of the compounds of the present application can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic base or organic base. Pharmaceutically acceptable salts may include various counterions, for example, counterions of inorganic or organic acids, counterions of inorganic or organic bases, or counterions provided by counterion exchange.
[0224] Acids and bases that can be used in the methods herein are known in the art. An acid catalyst is any acidic chemical substance that can be inorganic (e.g., hydrochloric acid, sulfuric acid, nitric acid, aluminum chloride) or organic (e.g., camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, ytterbium trifluoromethanesulfonate) in nature. Acids can be used in catalytic amounts or stoichiometric amounts to promote chemical reactions. Bases are any alkaline chemical substances that can be inorganic (e.g., sodium bicarbonate, potassium hydroxide) or organic (e.g., triethylamine, pyridine) in nature. Bases can be used in catalytic amounts or stoichiometric amounts to promote chemical reactions.
[0225] Alternatively, the salt of the starting material or intermediate can be used to prepare the salt form of the compound of the present application. The free acid or free base form of the compound of the present application can be prepared by corresponding base addition salts or acid addition salts, respectively. For example, the compound of the present application in the form of acid addition salts can be converted into corresponding free bases by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, etc.). The compound of the present application in the form of base addition salts can be converted into corresponding free acids by treating with a suitable acid (e.g., hydrochloric acid, etc.).
[0226] The compounds of the present application containing nitrogen can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (m-CPBA) and / or hydrogen peroxide) to provide other compounds of the present application. Therefore, when valence and structure permit, all nitrogen-containing compounds shown and claimed are considered to include the compounds shown and their N-oxide derivatives (which can be designated as N→O or N + -O -). In addition, in other cases, the nitrogen in the compounds of the present application can be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds can be prepared by oxidation of the parent amine with an oxidant such as m-CPBA. When valence and structure permit, all nitrogen-containing compounds shown and claimed are also considered to cover the compounds shown and their N-hydroxy (i.e., N-OH) and N-alkoxy (i.e., N-OR, where R is substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, C 1 -C 6 alkynyl, 3-14 membered carbocyclic ring or 3-14 membered heterocyclic ring) derivatives.
[0227] The prodrugs of the compounds of the present application can be prepared by methods known to those of ordinary skill in the art (e.g., for further details, see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, suitable prodrugs can be prepared by reacting the non-derivatized compounds of the present application with suitable carbamoylating agents (e.g., 1,1-acyloxyalkyl chloroformate, p-nitrophenyl carbonate, etc.). Specifically, the central N-acetic acid moiety and other similar carboxylic acid groups of the compounds of the present invention can be modified by techniques known in the art to produce effective prodrugs of the present invention.
[0228] The protected derivatives of the compounds of the present application can be prepared by methods known to those skilled in the art. A detailed description of techniques suitable for creating protecting groups and their removal can be found in "Protecting Groups in Organic Chemistry" by TW Greene, 3rd edition (John Wiley and Sons, Inc., 1999).
[0229] The compounds of the present application can be conveniently prepared or formed as solvates (e.g., hydrates) in the process of the present application. Hydrates of the compounds of the present application can be conveniently prepared by recrystallization from an aqueous / organic solvent mixture using organic solvents such as dioxin, tetrahydrofuran or methanol.
[0230] Optical isomers can be prepared by the procedures described herein or by resolving racemic mixtures from their respective optically active precursors. Resolving can be performed by chromatography in the presence of a resolving agent or by repeated crystallization or by some combination of these techniques known to those skilled in the art. More detailed information on the resolution can be found in Jacques et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981).
[0231] The synthesized compound can be separated from the reaction mixture and further purified by methods such as column chromatography, high pressure liquid chromatography or recrystallization. As will be appreciated by those skilled in the art, further methods for synthesizing compounds of the formula described herein will be apparent to those of ordinary skill in the art. In addition, various synthesis steps can be performed in alternating order or sequence to obtain the desired compound. In addition, the solvents, temperatures, reaction durations, etc. described herein are only for illustrative purposes, and those of ordinary skill in the art will recognize that changes in reaction conditions can produce the desired bridged macrocyclic products of the present application. Synthetic chemistry transformations and protecting group methods (protection and deprotection) that can be used to synthesize the compounds described herein are known in the art and include, for example, those described in books such as R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and PGM Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
[0232] Various functional groups can be added to modify the compounds of the present application by any synthetic method described herein to enhance selective biological properties. Such modifications are known in the art and include increasing the biopermeability to a given biological system (e.g., blood, lymphatic system, central nervous system), increasing oral availability, increasing solubility to allow administration by injection, changing metabolism and changing excretion rate modifications.
[0233] Biological assays
[0234] The biological activity of the compounds of the present application can be measured by various biochemical or cellular assays known to those of ordinary skill in the art. Non-limiting examples of methods for determining biological activity are discussed herein.
[0235] Pharmacokinetic characteristics of deuterated compounds
[0236] The stability of the compounds of the present application can be measured. Specifically, the stability in microsomes measured using the protocols described herein and / or WO 2020 / 132461 (which is incorporated herein by reference in its entirety) can be used to assess the compounds of the present application.
[0237] Evaluation of metabolic stability in human liver microsomes
[0238] The pharmacokinetics of the compounds of the present application can be determined after a single intravenous or oral administration to one or more test subjects (including mice, rats, dogs, etc.). Pharmacokinetic studies can be performed after intravenous (IV) and oral (PO) administration of the compounds of the present disclosure compared to non-deuterated compounds in three male Sprague-Dawley (SD) rats. Different doses can be used according to the administration route of the test subject, such as 1 mg / kg (IV) and 10 (PO) mg / kg. The test compound in the plasma can be measured and its value can be determined according to methods known in the art.
[0239] Pharmaceutical composition
[0240] In another aspect, a pharmaceutical composition is provided, comprising a therapeutically effective amount of the compound of the present application or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0241] The compounds of the present application can be administered as pharmaceutical compositions by any conventional route, in particular enterally (e.g., orally, for example, in the form of tablets or capsules), parenterally (e.g., in the form of injectable solutions or suspensions), or topically (e.g., in the form of lotions, gels, ointments or creams, or in the form of nasal cavities or suppositories).
[0242] A pharmaceutical composition comprising a compound of the present application in free form or in the form of a pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent can be manufactured by mixing, granulation or coating methods in a conventional manner. For example, an oral composition can be a tablet or a gelatin capsule comprising an active ingredient and a) a diluent, for example, lactose, glucose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) a lubricant, for example, silicon dioxide, talc, stearic acid, its magnesium salt or calcium salt and / or polyethylene glycol; for tablets, c) a binder, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone can also be included; if necessary, d) a disintegrant, for example, starch, agar, alginic acid or its sodium salt, or an effervescent mixture can also be included; and / or e) an adsorbent, a colorant, a flavoring agent and a sweetener. The injectable composition can be an aqueous isotonic solution or suspension, and the suppository can be prepared from a fat emulsion or suspension. The composition can be sterile and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solution promoters, salts and / or buffers for regulating osmotic pressure. In addition, they may also contain other therapeutically valuable substances. Suitable formulations for transdermal application include an effective amount of the compound of the present application and a carrier. The carrier may include an absorbable pharmacologically acceptable solvent to help pass through the host's skin. For example, a transdermal device may be in the form of a bandage, the bandage including a backing member, a reservoir containing the compound (optionally with a carrier), optionally a rate-controlling barrier (thereby delivering the compound to the host's skin at a controlled and predetermined rate over an extended period of time) and a tool for fixing the device to the skin. Matrix transdermal preparations may also be used. Suitable formulations for topical application, such as to the skin and eyes, are aqueous solutions, ointments, creams or gels well known in the art. Such additives may include solubilizers, stabilizers, tension enhancers, buffers and preservatives.
[0243] The pharmaceutical composition of the present application comprises a therapeutically effective amount of the compound of the present application formulated with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means any type of non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation aid. According to the judgement of the formulator, some examples of materials that can serve as pharmaceutically acceptable carriers include but are not limited to ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, ascorbic acid or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene polyoxypropylene block polymers, lanolin, sugars (such as lactose, glucose and sucrose); starches (such as corn starch and potato starch); cellulose and its derivatives (such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate); powdered tragacanth; malt; gelatin; talc; excipients (such as cocoa butter and suppository waxes); oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil); glycols (such as propylene glycol or polyethylene glycol); esters (such as ethyl oleate and ethyl laurate); agar; buffers (such as magnesium hydroxide and aluminum hydroxide); alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethanol and phosphate buffer solutions, and other non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), and coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may also be present in the composition.
[0244] The pharmaceutical compositions of the present application may be administered to humans and other animals orally, rectally, parenterally, intracisternal, intravaginal, intraperitoneal, topically (eg, by powders, ointments or drops), buccally or as an oral or nasal spray.
[0245] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (specifically, cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and aromatics.
[0246] Injectable preparations, such as sterile injectable aqueous or oily suspensions, can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions contained in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile, fixed oils are generally used as solvents or suspension media. For this purpose, any gentle fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectable preparations.
[0247] To prolong the effect of a drug, it is often necessary to slow the absorption of a drug injected subcutaneously or intramuscularly. This can be achieved by using a liquid suspension of a poorly water-soluble crystalline or amorphous substance. The absorption rate of a drug depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0248] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of the present application with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0249] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose (milk sugar) as well as high molecular weight polyethylene glycols and the like.
[0250] The active compound can also be in the form of microencapsulation with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings, controlled release coatings and other coatings known in the field of pharmaceutical formulation. In such solid dosage forms, the active compound can be mixed with at least one inert diluent such as sucrose, lactose or starch. It is common practice that such dosage forms can also include other materials except the inert diluent, such as tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form can also include a buffer.
[0251] In some embodiments, the pharmaceutical compositions of the present disclosure are solid dosage forms formulated for immediate release (IR).In some embodiments, the pharmaceutical compositions of the present disclosure are solid dosage forms formulated for extended release (ER).
[0252] As used herein, the term "immediate release formulation" refers to a composition comprising a compound of the present application that lacks a release-modifying structural element such as a matrix or coating.
[0253] As used herein, the term "extended release" refers to a mode of releasing an active ingredient from a pharmaceutical composition, wherein the time and / or rate of releasing the active ingredient is delayed or slowed down. A pharmaceutical composition formulated for extended release is a pharmaceutical composition comprising one or more structural features that have the effect of preventing the active ingredient from being released immediately after being administered to a subject. For example, in a pharmaceutical composition formulated for extended release, the active ingredient can be embedded in a matrix core that slowly degrades over time. Alternatively or additionally, the pharmaceutical composition can include a polymer coating that loses structural integrity over time, thereby allowing the release of the active ingredient previously wrapped by the coating.
[0254] In some embodiments, the pharmaceutical composition of the present application comprises a racemic mixture of deuterated analogs of the (R) and (S) enantiomers of idazoxan. In some embodiments, the pharmaceutical composition of the present application comprises a mixture of deuterated analogs of the (R) and (S) enantiomers of idazoxan enriched in the (R) enantiomer. In some embodiments, the pharmaceutical composition of the present application comprises a deuterated analog of the (R) enantiomer of idazoxan. In some embodiments, the pharmaceutical composition of the present application comprises a racemic mixture of deuterated analogs of the (R) and (S) enantiomers of idazoxan enriched in the (S) enantiomer. In some embodiments, the pharmaceutical composition of the present application comprises a deuterated analog of the (S) enantiomer of idazoxan.
[0255] Without wishing to be bound by theory, it is believed that administration of a deuterated analog of (R)-idazoxan (the inactive enantiomer of idazoxan) to a subject results in the formation of a reservoir of the deuterated analog of (R)-idazoxan in the subject. It is believed that over time, the reservoir of the deuterated analog of (R)-idazoxan is converted to (S)-idazoxan. It is believed that over time, the conversion of (R) to (S) results in sustained exposure to the deuterated analog of (S)-idazoxan, for example, at concentrations within the therapeutic window of idazoxan. This means that formulations of deuterated analogs of (R)-idazoxan may have an improved ability to maintain the deuterated (S)-idazoxan AUC within an optimal range, thereby demonstrating a desired therapeutic effect superior to formulations of deuterated analogs of (S)-idazoxan and racemic deuterated analogs of idazoxan.
[0256] The dosage forms for topical or transdermal administration of the compounds of the present application include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed with a pharmaceutically acceptable carrier and any required preservatives or buffers that may be required under aseptic conditions. Ophthalmic preparations, ear drops, ophthalmic ointments, powders and solutions are also encompassed within the scope of the present application.
[0257] In addition to the active compounds of the present application, the ointments, pastes, creams and gels may contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0258] In addition to the compounds of the present application, powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may also contain customary propellants, for example chlorofluorocarbons.
[0259] Transdermal patches have the added advantage of controlled delivery of compounds to the body. Such dosage forms can be prepared by dissolving or dispensing the compound in an appropriate medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0260] For any compound, the therapeutically effective amount can be estimated first in cell culture assays (e.g., cell culture assays of tumor cells) or in animal models (usually rats, mice, rabbits, dogs, or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose that is lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as LD 50 / ED 50 Pharmaceutical compositions that exhibit high therapeutic indices are preferred. The dosage may vary within this range depending on the dosage form employed, patient sensitivity, and route of administration.
[0261] The dosage and mode of administration are adjusted to provide sufficient levels of one or more active agents or to maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, time and frequency of administration, one or more drug combinations, reaction sensitivity and tolerance / response to treatment. Long-acting pharmaceutical compositions may be administered once every 3 to 4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.
[0262] The amount of active ingredient (e.g., a disclosed compound or its salt, hydrate, solvate or isomer preparation) in a unit dose composition is an effective amount and varies according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to make conventional changes to the dosage according to the age and illness of the patient. The dosage will also depend on the route of administration. A variety of routes are covered, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc. The dosage form for topical or transdermal administration of the compound of the present application includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In some embodiments, the active compound is mixed with a pharmaceutically acceptable carrier and with any preservatives, buffers or propellants that may be needed under aseptic conditions.
[0263] The pharmaceutical composition containing the active compound of the application can be manufactured in a generally known manner, for example, by conventional mixing, dissolving, granulating, preparing dragees, grinding, emulsifying, encapsulating, embedding or lyophilizing processes. The pharmaceutical composition can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers, which include excipients and / or adjuvants that help to process the active compound into pharmaceutically usable preparations. Of course, suitable preparations depend on the selected route of administration.
[0264] The preparation and administration techniques of the compounds disclosed in the present application can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and pharmaceutically acceptable salts thereof are combined with pharmaceutically acceptable carriers or diluents for use in pharmaceutical preparations. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compound will be present in such pharmaceutical compositions in a sufficient amount to provide the desired dosage within the range described herein.
[0265] How to use
[0266] The compounds of the present disclosure are also used in the manufacture of medicaments, in particular, in the manufacture of medicaments intended for the prophylactic and / or therapeutic treatment of disorders of the central nervous system. In some embodiments, the medicament in tablet form is intended for the treatment of depression, Parkinson's disease and / or severe psychiatric disorders, such as schizophrenia and schizoaffective disorders.
[0267] In some embodiments, the application provides a method for treating or preventing any disease, disorder, and condition described herein, wherein the subject is a human. In some embodiments, the application provides a method of treatment. In some embodiments, the application provides a method of prevention.
[0268] In some embodiments, the brain disorder is selected from Alzheimer's disease, ataxia, Huntington's disease, Parkinson's disease, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, motor neuron disease, multiple system atrophy or progressive supranuclear palsy, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, frontal lobe dementia or mixed dementia, migraine, tension headache, cluster headache, depression, refractory depression, postpartum depression, psychotic depression, seasonal affective disorder, major depressive disorder, persistent depressive disorder, bipolar depression, premenstrual mood disorder, addiction, substance use disorder, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, psychosis, schizophrenia, stroke, traumatic brain injury, generalized anxiety disorder, panic disorder, social anxiety disorder, one or more phobia-related disorders, separation anxiety disorder, substance use disorder or schizoaffective disorder, or a combination thereof.
[0269] In some embodiments, the brain disorder is schizoaffective disorder.In some embodiments, the brain disorder is schizophrenia.
[0270] In some embodiments, the brain disorder is schizoaffective disorder.In some embodiments, the brain disorder is a type of dementia.
[0271] In some embodiments, the brain disorder is schizoaffective disorder.In some embodiments, the brain disorder is Alzheimer's disease.In some embodiments, the pharmaceutical composition is administered in combination with a second therapeutic agent.
[0272] In some embodiments, the pharmaceutical composition is administered in combination with an antipsychotic. In some embodiments, the pharmaceutical composition is administered in combination with a dopamine type 2 receptor antagonist (D2 antagonist).
[0273] In some embodiments, the pharmaceutical composition is administered for a period of one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, or ten weeks. In some embodiments, the pharmaceutical composition is administered for a period of one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, or twelve months. In some embodiments, the pharmaceutical composition is administered for a period of one year, two years, three years, four years, five years, six years, seven years, eight years, nine years, ten months, eleven years, or twelve years. In some embodiments, the subject is administered the pharmaceutical composition for life.
[0274] According to the foregoing, the present application provides a method for preventing or treating any disease or condition described herein in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the present application or its enantiomer, diastereomer, stereoisomer or pharmaceutically acceptable salt, or a pharmaceutical composition of the present application. For any of the above uses, the required dosage will vary depending on the mode of administration, the specific illness to be treated, and the desired effect.
[0275] Combination therapy may include further combining the subject compound with one or more other biologically active ingredients. For example, the compound of the present application can be used in combination with other pharmaceutically active compounds, preferably a compound that can enhance the effect of the compound of the present application. The compound of the present application can be used simultaneously (as a single preparation or a separate preparation) or sequentially with other drug therapies or treatment methods. In general, combination therapy refers to the use of two or more drugs in a single treatment cycle or course of treatment.
[0276] As used herein, the term "subject" refers to a mammal. Thus, a subject refers to, for example, a dog, a cat, a horse, a cow, a pig, a guinea pig, etc. Preferably, the subject is a human. When the subject is a human, the subject may be referred to herein as a patient.
[0277] "Treat," "treating" and "treatment" refer to a method of alleviating or alleviating a disease and / or its attendant symptoms.
[0278] As used herein, "preventing" or "prevent" describes the reduction or elimination of the occurrence of symptoms or complications of a disease, disorder or condition.
[0279] Unless the context clearly dictates otherwise, the terms "disease(s)," "disorder(s)" and "condition(s)" are used interchangeably.
[0280] As used herein, the term "therapeutically effective amount" of the compound or pharmaceutical composition of the present application means an amount of the compound or pharmaceutical composition sufficient to alleviate the symptoms of the subject's condition. As is well known in the medical field, a therapeutically effective amount of the compound or pharmaceutical composition of the present application will be at a reasonable benefit / risk ratio applicable to any medical treatment. However, it should be understood that the total daily dosage of the compounds and compositions of the present application will be determined by the attending physician within the scope of reliable medical judgment. For any specific subject, a specific adjustment (e.g., inhibition or stimulation) dose will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound used; the specific composition used; the age, weight, general health, sex and diet of the subject; the time of administration, route of administration and the excretion rate of the specific compound used; the duration of treatment; drugs used in combination or in concert with the specific compound used; and similar factors well known in the medical field.
[0281] As used herein, the phrase "pharmaceutically acceptable" refers to compounds, materials, compositions, carriers and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0282] As used herein, the term "pharmaceutically acceptable salt" refers to those salts of compounds formed by the process of the present application, which are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., within the scope of reasonable medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final separation and purification of the compounds of the present application, or by reacting the free base or acid functional group with a suitable acid or base alone.
[0283] Examples of pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, 7-toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cation salts formed when appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates and arylsulfonates.
[0284] As used herein, the term "pharmaceutically acceptable ester" refers to an ester of a compound formed by the process of the present application, which hydrolyzes in vivo and includes those esters that readily decompose in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, ester groups derived from pharmaceutically acceptable aliphatic carboxylic acids (particularly alkanoic acids, alkenoic acids, cycloalkanoic acids, and alkanedioic acids), wherein each alkyl or alkenyl moiety advantageously has no more than 6 carbon atoms. Examples of specific esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates, and ethylsuccinates.
[0285] As used herein, the term "pharmaceutically acceptable prodrug" refers to a prodrug of a compound formed by the process of the present application, which is suitable for contact with the tissues of humans and lower animals within the scope of sound medical judgment but has excessive toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio, and is effective for its intended use, and, where possible, the zwitterionic form of the compound of the present application.
[0286] As used herein, "prodrug" means a compound that is transformable in vivo by metabolic means (eg, by hydrolysis) to provide any of the compounds represented by the formulae of the present application. Various forms of prodrugs are known in the art, for example, as Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (eds.), Methods in Enzymology, Vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (eds.). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38 (1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology", John Wiley and Sons, Ltd. (2002).
[0287] "Pharmaceutically acceptable excipient" means an excipient that can be used to prepare a pharmaceutical composition, which is generally safe, non-toxic, and has no biological and other adverse effects, and includes excipients acceptable for veterinary as well as human pharmaceutical use. As used in this specification and claims, "pharmaceutically acceptable excipient" includes both one or more such excipients.
[0288] The present application also encompasses pharmaceutical compositions containing pharmaceutically acceptable prodrugs of compounds of the present application, and methods for treating diseases by administering the prodrugs. For example, compounds of the present application having free amino groups, amide groups, hydroxyl groups or carboxyl groups can be converted into prodrugs. Prodrugs include compounds in which amino acid residues or polypeptide chains of two or more (e.g., two, three or four) amino acid residues are covalently attached to free amino groups, hydroxyl groups or carboxyl groups of compounds of the present application via amide or ester bonds. Amino acid residues include, but are not limited to, 20 naturally occurring amino acids that are usually specified with three-letter symbols, and also include 4-hydroxyproline, hydroxylysine, demosine, isodesine, 3-methylhistidine, norvaline, β-alanine, γ-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Other types of prodrugs are also encompassed. For example, free carboxyl groups can be derived into amides or alkyl esters. Free hydroxyl groups can be derivatized using groups including but not limited to hemisuccinate, phosphate, dimethylaminoacetate and phosphoryloxymethoxycarbonyl, as described in Advanced Drug Delivery Reviews, 1996, 19, 1-15. Also included are carbamate prodrugs of hydroxyl and amino groups, such as carbonate prodrugs, sulfonates and sulfates of hydroxyl groups. Also encompassed are hydroxyl group derivatizations to (acyloxy) methyl ethers and (acyloxy) ethyl ethers, wherein the acyl group can be an alkyl ester, optionally substituted by groups including but not limited to ether, amine and carboxylic acid functional groups, or wherein the acyl group is an amino acid ester as described herein. This type of prodrug is described in J.Med.Chem.1996, 39, 10. Free amines can also be derivatized to amides, sulfonamides or phosphoramides. All of these prodrug moieties can include groups including but not limited to ether, amine and carboxylic acid functional groups.
[0289] The combinations of substituents and variables contemplated by this application are only those combinations that result in the formation of stable compounds. As used herein, the term "stable" refers to having stability sufficient to allow manufacturing and maintaining the integrity of the compound for a sufficient period of time to enable it to be used for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
[0290] When any variable (e.g., R 1 ) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with one or more R moieties, each occurrence of R is selected independently of the definition of R. In addition, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds within the normal valencies of the designated atoms.
[0291] In addition, some compounds of the present application have one or more double bonds, or one or more asymmetric centers. Such compounds can be used as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis or trans or E or Z type diisomeric forms and can be defined as (R)- or (S)-, or (D)- or (L-) other stereoisomer forms from the absolute stereochemistry for amino acids. When the compounds described herein contain olefinic double bonds or other geometric asymmetric centers, unless otherwise specified, the compound is intended to include both E and Z geometric isomers. The configuration of any carbon-carbon double bond that occurs herein is selected for convenience only and is not intended to specify a specific configuration, unless so described in the text; therefore, the carbon-carbon double bond arbitrarily described herein as trans can be cis, trans, or a mixture of the two in any proportion. The application clearly includes all such isomeric forms of such compounds.
[0292] In addition, the compounds of the present application, such as salts of the compounds, can exist in hydrated or non-aqueous (anhydrous) forms, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.
[0293] "Solvate" means a solvent addition form containing either stoichiometric or non-stoichiometric amounts of solvent. Some compounds tend to trap fixed molar ratios of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with a molecule of a substance, where the water remains in its molecular state as H 2 O.
[0294] Treatment
[0295] In some embodiments, the pharmaceutical compositions of idazoxan disclosed herein can be used to treat a disease or condition. In some embodiments, the disease or condition is a brain condition. In some embodiments, the brain condition is a neurodegenerative condition such as Alzheimer's disease, ataxia, Huntington's disease, Parkinson's disease, Creutzfeldt-Jakob disease, amyotrophic sclerosis, motor neuron disease, multiple system atrophy, or progressive supranuclear palsy. In some embodiments, the brain condition is a dementia such as vascular dementia, Lewy body dementia, frontotemporal dementia, frontal dementia, or mixed dementia.
[0296] In some embodiments, the disease or condition is diabetes.
[0297] In some embodiments, the brain disorder is migraine, tension headache, cluster headache.
[0298] In some embodiments, the brain disorder is a psychological disorder such as depression, refractory depression, postpartum depression, psychotic depression, seasonal affective disorder, major depressive disorder, persistent depressive disorder, bipolar depression, premenstrual mood disorder, addiction, substance use disorder, anxiety disorder, post-traumatic stress disorder, suicidal ideation, major depressive disorder, psychosis, schizophrenia, stroke, traumatic brain injury, generalized anxiety disorder, panic disorder, social anxiety disorder, one or more phobia-related disorders, separation anxiety disorder, or substance use disorder. In some embodiments, the brain disorder is schizophrenia.
[0299] In some embodiments, the brain disorder is schizoaffective disorder. In some embodiments, the schizoaffective disorder is bipolar schizoaffective disorder. In some embodiments, the schizoaffective disorder is depressive schizoaffective disorder. In some embodiments, the schizoaffective disorder is mixed schizoaffective disorder.
[0300] In some embodiments, the disease or disorder is a musculoskeletal pain disorder, including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle spasms.
[0301] In some embodiments, the present disclosure provides methods of treating female reproductive health conditions including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), postpartum depression, and menopause.
[0302] In some embodiments, pharmaceutical compositions of idazoxan can be used in combination to treat brain disorders.
[0303] In some embodiments, the pharmaceutical composition of idazoxan has anti-addiction properties, anti-psychotic properties, anti-depressant properties, antianxiety properties, or a combination thereof.
[0304] The compositions of idazoxan disclosed herein can be used to increase neuronal plasticity. The compounds disclosed herein can also be used to treat any brain disorder. The compounds disclosed herein can also be used to increase at least one of the translation, transcription or secretion of neurotrophic factors.
[0305] Combination therapy
[0306] In some embodiments, a serotonin receptor modulator, such as a modulator of serotonin receptor 2A (5-HT 2A Regulators, such as 5-HT 2A Agonists) are used to treat brain disorders. The pharmaceutical composition of the present disclosure can be combined with 5-HT 2AThe second therapeutic agent of the combination therapy as described herein is used in combination with a second therapeutic agent. In such cases, the second therapeutic agent can be an agonist or an antagonist. Serotonin receptor modulators that can be used as the second therapeutic agent of the combination therapy as described herein are known to those skilled in the art and include, but are not limited to, ketanserin, fluricerin (MDL-100907), eliserin (SR-46349), pimaserin (ACP-103), glaiserin (MDL-11939), ritanserin, flibanserin, netanserin, blonanserin, mianserin, mirtazapine, rolopidone (CYR-101, MIN-101), quetiapine, olanzapine, atanserin, acepromazine, nefazodone, risperid ... ketone, pravanserin, AC-90179, AC-279, adaserin, farnanserin, HY10275, benzyltryptamine, butanserin, mianserin, efserin, lidanserin, perlanserin, saganserin, tropanserin, lorcaserin, ICI-169369, methysergotamine, trazodone, cinipride, cyproheptadine, brepirazole, cariprazine, agomelatine, stopirone, 1-(1-naphthyl)piperazine, LY-367265, pilampirone, methylergoline, deramciclane, ampazid, cinaserin, LY-860 57, GSK-215083, cyanomemazine, mesulergine, BF-1, LY-215840, ergoxol, spiramide, LY-53857, anergine, LY-108742, pipampirone, LY-314228, 5-I-R91150, 5-MeO-NBpBrT, 9-aminomethyl-9,10-dihydroanthracene, niprazine, SB-215505, SB-204741, SB-206553, SB-242084, LY-272015, SB-2432 13. SB-200646, RS-102221, zotepine, clozapine, chlorpromazine, sertindole, iloperidone, paliperidone, asenapine, amisulpride, aripiprazole, lurasidone, ziprasidone, lumepirone, perospirone, mosapramine, AMDA (9-aminomethyl-9,10-dihydroanthracene), methiothepine, xanomeline, buspirone, extended-release forms of olanzapine (e.g., ZYPREXARELPREVV), extended-release forms of quetiapine, extended-release forms of risperidone (e.g., Risperdal Consta), extended-release paliperidone (e.g., Invega Sustenna and Invega Trinza), extended-release fluphenazine decanate (e.g., Prolixin Decanoate), extended-release aripiprazole lauroxil (e.g., Aristada), extended-release aripiprazole (e.g., Abilify Maintena), 3-(2-(4-(4-fluorobenzoyl)piperazin-1-yl)ethyl)-5-methyl-5-phenylimidazolidine-2-yl,4-dione, 3-(2-(4-dibenzylpiperazin-1-yl)ethyl)-5-methyl-5-phenylimidazolidine-2,4-dione, 3-(3-(4-(2-fluorophenyl)piperazin-1-yl)propyl)-5-methyl-5-phenylimidazolidine-2,4-dione, 3-(3-(4-(3-fluorophenyl)piperazin-1-yl)propyl)-5-methyl-5-phenylimidazolidine-2,4-dione, -(4-fluorophenyl)piperazin-1-yl)propyl)-5-methyl-5-phenylimidazolidine-2,4-dione, 3-(3-(4-(4-fluorobenzoyl)piperazin-1-yl)propyl)-5-methyl-5-phenylimidazolidine-2,4-dione, 3-(2-(4-(4-fluorobenzoyl)piperazin-1-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione, 3-(2-(4-(4-fluorobenzoyl)piperazin-1-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione, 3-(3-(4-(2-fluorophenyl)piperazin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione, 3-(3-(4-(3-fluorophenyl)piperazin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione, -dione, 3-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione and 3-(3-(4-(4-fluorobenzoyl)piperazin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analog, derivative, prodrug or combination thereof. In some embodiments, the serotonin receptor modulator used as a second therapeutic agent is pimaserin or a pharmaceutically acceptable salt, solvate, metabolite, derivative or prodrug thereof. In some embodiments, the serotonin receptor modulator is administered prior to the compounds of the present disclosure, such as about three hours or about one hour prior to administration of the compounds disclosed herein. In some embodiments, the serotonin receptor modulator is administered up to one hour prior to the compounds of the present disclosure. Therefore, in some embodiments of the combination therapy with the compounds of the present disclosure, the second therapeutic agent is a serotonin receptor modulator. In some embodiments, the second therapeutic agent serotonin receptor modulator is provided in a dose from about 10 mg to about 350 mg. In some embodiments, the serotonin receptor modulator is provided in a dose of about 20 mg to about 200 mg. In some embodiments, the serotonin receptor modulator is provided in a dose of about 10 mg to about 100 mg. In certain such embodiments, the compounds of the present application are provided in a dose of about 10 mg to about 100 mg, or about 20 mg to about 200 mg, or about 15 mg to about 300 mg, and the serotonin receptor modulator is provided in a dose of about 10 mg to about 100 mg. ,
[0307] In some embodiments, dopamine receptor modulators, such as modulators of type 2 dopamine receptors (D2 modulators, e.g., D2 agonists) are used to treat brain disorders. The pharmaceutical compositions of idazoxan disclosed herein can be used in combination with a second therapeutic agent that is also a D2 modulator. In such cases, the second therapeutic agent can be an agonist or an antagonist. Dopamine receptor modulators that can be used as a second therapeutic agent in combination therapies as described herein are known to those of skill in the art and include, but are not limited to, roloperidone (CYR-101, MIN-101), quetiapine, olanzapine, atanserin, acepromazine, nefazodone, risperidone, trazodone, brepirazole, cariprazine, agomelatine, stopirone, zotepine, clozapine, chlorpromazine, sertindole, iloperidone, paliperidone, asenapine, amisulpride, aripiprazole, lurasidone, ziprasidone, lumepirone, perospirone, mosapramine, xanomeline, buspirone, an extended release form of olanzapine (e.g., ZYPREXARELPREVV), an extended release form of quetiapine, an extended release form of risperidone (e.g., Risperdal Consta), an extended release form of paliperidone (e.g., Invega Sustenna and Invega Trinza), extended release form of fluphenazine deco (including Prolixin Decanoate), extended release form of aripiprazole lauroyl (including, Aristada), extended release form of aripiprazole (including, Abilify Maintena) or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analog, derivative, prodrug or combination thereof. In some embodiments, the dopamine receptor modulator is administered before the compound of the present disclosure, such as about three hours or about one hour before the administration of the compound disclosed herein. In some embodiments, the dopamine receptor modulator is administered up to one hour before the compound of the present disclosure. Therefore, in some embodiments of the combination therapy with the compound of the present disclosure, the second therapeutic agent is a dopamine receptor modulator. In some embodiments, the second therapeutic agent dopamine receptor modulator is provided in a dose of about 10 mg to about 350 mg. In some embodiments, the dopamine receptor modulator is provided in a dose of about 20 mg to about 200 mg. In some embodiments, the dopamine receptor modulator is provided in a dose of about 10 mg to about 100 mg. In certain such embodiments, the compound of the present application is provided at a dose of about 10 mg to about 100 mg, or about 20 mg to about 200 mg, or about 15 mg to about 300 mg, and the dopamine receptor modulator is provided at a dose of about 10 mg to about 100 mg.
[0308] US Pre-Grant Publication No. 20060281735 and US Pat. No. 5,663,167 disclose combinations of idazoxan and a D2 antagonist and are incorporated herein by reference.
[0309] In some embodiments, the pharmaceutical composition of idazoxan can be used in combination with a second agent to treat Alzheimer's disease. In some embodiments, the pharmaceutical composition of idazoxan is used in combination with a cholinesterase inhibitor and / or an NMDA receptor antagonist. Exemplary and non-limiting agents for treating Alzheimer's disease that can be administered in combination with the pharmaceutical composition of idazoxan include Leqembi (lencanetumab-irmb), donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Namenda), memantine (Namzaric), Ginkgo extract, Aducanumab, 3APS, 3TC, AAB-001, AADvac1, AAV2-BDNF gene therapy, ABBV-8E1 2. ABBV-552, ABBV-916, ABT-089, ABT-126, ABT-288, ABT-384, ABvac40, AC-1204, AC-3933, AC-OLE-01-VA, ACC-001, acetyl-L-carnitine, ACI-24.060, ACI-35.030, Acitretin, active tPBM, ACU193, AcumorXL, AD-35, adenosine triphosphate, Adlarity, Aducanumab, Aduhelm, AGB101, Akpha E, AL001, AL002, Albumin 5%, Albumin 20%, Alfoatirin, Allogeneic MSC, Allopregnanolone, ALN-APP, ALZ-101, Alzhok, ALZT-OP1a, ALZT-OP1b, Amlodipine, AMX0035, AN-1792, ANAVEX2-73, APH-1105, APNmAb005, Aqua Gem-E, Aquasol E, AQW051, AR1001, ARB, Aricept, Aricept ODT, Aripiprazole, Armofenib, Astaxanthin, AstroStem, Atabecestat, ATH-1017, Atomoxetine Hydrochloride, Atorvastatin, Atorvastatin Calcium, Atropine, AV-1959D, Avagacestat, AVE1625, AVP-786, AVP-923-30, AXS-05 (Dextromethorphan-Bupropion), AZD0530, AZD1446, AZD3480, AZD3480, AZD5213, Azeliragon, BAC, Bapineuzumab, Baricitinib, Belsomra, Benfotiamine, Bepranemab, Bexarotene, BI 409306, BI425809, bifenoxanol, BIIB080, BIIB092, BMS-708163 / BPDO-1603, BPN14770, breprazol, bromocriptine, bryostatin, bryostatin 1, Buntanetap, buprenorphine, C-11ER-176, CAD106 immunotherapy, canakinumab, caprylic triglyceride, octinin, carvedilol, CB-AC-02, CCB, celecoxib (Celebrex), CERE-110, cerebrolysin, CHF 5074, Choline glycerol, Cholinergic antagonist, Cholinesterase inhibitor, Cilostazol, Circadin, Citalopram, CMS121, CNP520, COR388, CORT108297, CPC-201, Crenezumab, CT1812, CX516, CY6463, DAOI-A, DAOI-B, DAOI-C, Dapagliflozin, Daratumumab injection, Dasatinib, DCB-AD1, Deferiprone, Delta-9-tetrahydrocannabinol Phenol, dexmethylphenidate, dextroamphetamine, DHP1401, Dimebon, valproic acid, valproic acid ER, dl-α-tocopherol, docosahexaenoic acid, donanemab, donepezil, donepezil / memantine, donepezil hydrochloride, dronabinol, DSPE-DOTA-Gd liposome injection, E-400Clear, E-600, E-Gems, E2020, E2609, E2814, Ebicomb, Ebixa, EGb761, EHT 0202 Etablissette, Elenbecestat (E2609), ELND005, Elontril, Empagliflozin, Emtriva capsules, ENA713, E Pherol, Epigallocatechin gallate, Dihydroergotamine mesylate, Escitalopram, Escitalopram oxalate, Estrogen, Etanercept, Ethosuximide, EVP-0962, EVP-6124, EX039, Exelon, Exendin-4SC, ExPlas, Filgrastim, FK962, Florbetaben (BAY94-9172), Flos gossypii flavonoids, Flutemetamol, Formoterol A, Gabapentin Encarb, Galantamine, Galantamine hydrobromide, Galsya XL, Gantenerumab, Gastric Retention Cysteine Zinc, GatalinXL, gonadorelin acetate, GRF6019, GSK239512, guanfacine, GV-971, GV1001, haloperidol, HB-adMSCs, HF0220, human mesenchymal stem cells and lactated Riunger's solution, huperzine A, hydrocodone, hydralazine hydrochloride, hydrocodone / APAP, hydroxypropyl-β-cyclodextrin, IBC-Ab002, eicosapentaenoic acid ethyl ester, ID1201, idalopirdine, IGC-AD1, idalopirdine, intravenous immunoglobulin (human), immunoglobulin, indomethacin, insulin, insulin glulisine, IONIS MAPTRx, isotretinoin, ITI-007, JACI-35.054, JNJ-54861911, JNJ-63733657, KarXT. Prazosin, L-arginine, L-serine, Ladotige hemi-tartrate, Lanabecestat, Lencanelumab, Lecozotan SR, Lemborexant, Lenalidomide, Leqembi, Leuprorelin acetate, Levetiracetam, Levodopa, Liraglutide, Lithium, Lithium carbonate, LM11A-31-BHS, LMTM, Long-chain triglycerides, Lornoxicam, Losartan, Lovastatin, Lu AE58054, Lu AF87908, LX1001, LY450139, LY450139 dihydrate, LY451395, LY2062430, LY2886721, LY3154207, LY3202626, LY3372689, LY3372993, MABT5102A, Masitinib, Masupirdine, MEDI1814 (anti-amyloid β mAb), medroxyprogesterone, MEM 1003, MEM 3454, memantine, memantine hydrochloride, metformin, methylene blue, methylphenidate, MIB-626, mifepristone, minocycline, mirtazapine, MK-1942, MK-2214, MK-7622, MK0249, MK0677, MK0952, MLC601, MLC901, modafinil, montelukast, montelukast buccal film, MPC-7869, MSDC-0160, MT-4666, MW150, nabilone, namanda XR, namanda, Namzaric, NP03, naproxen, naproxen sodium (Aleve), NE3107, nefiracetam, neflamapimod, netanserin, nemdatine, neramexan, NewGam10% IVIG, NGP 555, NIC5-15, nicotinamide riboside, nilotinib, nilotinib BE, nilvadipine, NIO752, NP031112, NPT 2042, NS2330, Nuedexta, Obicetrapib, Octagam 10%, Octaplasma, Octahydroaminoacridine succinate, Olanzapine, Ω3PUFA, ONO-2506PO, ORM-12741, ORY-2001, Acetaminophen, PBT2, Pepinemab, Perindopril, Perphenazine, PF-01913539, PF-04360365, PF-04447943, PF-04494700, PF-05212377, PF-0664867 1. Pimasserin, Pimasserin tartrate, Pioglitazone, Piracetam, Pirometine, PM012, Posiphen, PPI-1019, PQ912, Prednisone, Probucol, Aldesleukin, PRX-03140, PTI-125, PXT00864, PYM50028, QS-21, Quercetin, Quetiapine, Quetiapine fumarate, Raloxifene, Ramelteon, Ramipril, Rapamycin, Rasagiline, Razadyne, RazadyneER, RB-ADSC, regulatory T cells, REM0046127, Reminyl, Remternetug, reserpine, resveratrol, rifaximin, liraglutide, riluzole, risperidone, rivastigmine, rivastigmine patch, RO4602522, RO5313534, RO7126209, rofecoxib, rosiglitazone, rosiglitazone XR, rotigotine transdermal patch, RPh201, RVT-101, S-equol, S47445, SAGE-718, SAM-531, SAR110894, sargramostim, SB-742457, SCI-110, Seltorexant, semestad, semaglutide, semaglutide Semorinemab, Senicapoc, Sertraline, SGS742, SHR-1707, simufilam, simvastatin, SK-PC-B70M, SLS-005, SNK01, sodium mannooligosaccharide dihydrate, sodium mannitol, sodium oxybate, Solanezumab, Solifenacin, Spironolactone, SR57667B, SRA-333, SSR180711C, ST101, Sulbutiamine, SUVN-502, Suvorexan, T-817MA, T-817MA-H, T-817MA-L, T2:C100, T3D-959, Tacrine, Tacrolimus, Tasalidin, Tamibarotene, Tandospirone Citrate, Tau Mab, TB006, telmisartan, tetrahydrobiopterin, TH9507 human growth hormone-releasing hormone, thalidomide, thioethylperazine, tideglusib, tilavonemab, TPI 287 (next-generation taxane), Tramisat, Traneurocin, Transdermal Estradiol, Transdermal Methylphenidate, Trazodone, Tricaprilin, Trorizole, TRx0014, TRx0237, Tryptophan, TW001, UB-311, UCMSCs, Valaciclovir / Valacyclovir, Valproate, Varenicline, Venlafaxine, Verubecestat, VI-1121, Vitamin E, VP4896, VT301, VX-745, Xaliproden (SR57746A), Xanamem, XPro1595, Zagotenemab, Zolpidem, Zoplicone, Zydena
[0310] In some embodiments, monoclonal or polyclonal antibodies (such as antibodies against beta-amyloid) are used to treat brain disorders. The pharmaceutical compositions of idazoxan disclosed herein can be used in combination with a second therapeutic agent that is also a monoclonal or polyclonal antibody. For example, the pharmaceutical compositions of idazoxan disclosed herein can be used in combination with aducanumab or Leqembi (lencanerizumab-irmb).
[0311] Example
[0312] The disclosure is further illustrated by the following examples, and the embodiments and synthesis schemes should not be construed as limiting the disclosure in scope or spirit to the specific procedures described herein. It should be understood that the examples are provided to illustrate certain embodiments and are not intended to limit the scope of the disclosure. It should be further understood that various other embodiments, modifications, and equivalents that may be conceivable to those skilled in the art may be adopted without departing from the spirit of the disclosure and / or the scope of the appended claims.
[0313] NMR analysis
[0314] The analysis was performed on a 400 MHz NMR spectrometer using deuterated chloroform, deuterated methanol or deuterated dimethyl sulfoxide as solvent ( 1 H. 13 C and 19 F NMR). The chemical shift (d) of each signal is measured in parts per million (ppm) relative to the residual solvent peak, and the multiplicity and associated coupling constant (J) are reported where applicable. Data are reported as (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet).
[0315] Agilent LC-MS analysis method
[0316] Instrument: Agilent 1260 infinity HPLC coupled to Agilent 6130 single quadrupole mass spectrometer.
[0317] Column: Phenomenex Kinetex XB-C 18 ,50x 4.6mm,2.6μm
[0318] Elution curve
[0319]
[0320] Flow rate: 2 mL / min; Detector wavelength: 225 ± 50 nm bandwidth; Column temperature: 40 °C; Injection volume: 1 μl; MS parameters: Scan in ES + / - and APCI, scan range 70–1000 m / z; Needle wash: Wash with MeOH in vial 4, autosampler set to perform 5 needle washes (wash the outside of the needle before injecting the sample); Sample preparation: Prepare 0.5–1.0 mg / ml solutions in acetonitrile or DMSO depending on the solubility characteristics of the sample.
[0321] Waters Alliance LC-MS Analytical Method
[0322] Acid method (named Formic_8min)
[0323] Instrumentation: Waters 2795 Alliance HPLC system equipped with 2996 PDA detector and Micromass ZQ mass spectrometer detector.
[0324] Column: Gemini C18, 5μm, 50x 4.6mm ID
[0325] Mobile phase A: 0.1% formic acid in water
[0326] Mobile phase B: 100% acetonitrile
[0327] Gradient program (total run time per injection 8 minutes):
[0328] time Mobile phase A Mobile phase B 0.0 95 5 0.6 95 5 6.50 2 98 7.50 2 98 7.60 95 5 8.00 95 5
[0329] Flow rate: 1 ml / min; injection volume: 10 μl; column oven temperature: 40°C; detector: PDAUV, 190–400 nm, also fixed λ at 225 nm; mass spectrometry parameters: MS scan with ES+ and ES-, range of M / Z 100–1000; cleaning solvent is involved in the injection.
[0330] Example 1: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-5,6,7,8-d 4 )-4,5-dihydro-1H-imidazole (Compound 4)
[0331]
[0332] Step 1: (3,4,5,6-d 4 )-Benzene-1,2-diol
[0333] To a suspension of benzene-1,2-diol (1.00 g, 9.08 mmol) in deuterated water (20.0 mL, 1108 mmol) in a 10-20 mL Biotage microwave vial, potassium tert-butoxide (510 mg, 4.54 mmol) was added in one portion with stirring. The vial was placed under N 2 The mixture was stirred at 40 ℃ for 15 hours under a sealed atmosphere and then heated to 140 ° C for 15 hours (Biotage Initiator microwave oven). The mixture was extracted with EtOAc (5 x 50 mL) and the combined organic layers were concentrated under reduced pressure to give an oil which solidified after standing. The crude product was triturated with hexane, isolated by filtration and washed with hexane to give the title compound (600 mg, 57%) as a solid. Retention time 1.079 minutes; C 6 H 2 D 4 O 2 m / z = [MH] + Calculated value 113.0; Measured value 113.0; 1 H NMR (400 MHz, CDCl 3 )δ5.14(2H,s). The deuterium incorporation rate of the compound was determined to be 97% by quantitative NMR using maleic acid as a reference standard.
[0334] Step 2: 2,3-Dihydrobenzo[b][1,4]dioxin-2-carbonitrile-5,6,7,8-d 4
[0335] To (3,4,5,6-d 4 )-benzene-1,2-diol (600 mg, 5.26 mmol) and K 2 CO 3 To a solution of 2-chloroprop-2-enenitrile (1.45 g, 10.5 mmol) in acetone (12 ml) was added 2-chloroprop-2-enenitrile (460 mg, 5.26 mmol) in one portion. The mixture was heated to 50 °C and stirred for 18 hours. The mixture was concentrated under reduced pressure and the brown viscous residue was concentrated under H 2 O (100 mL) and Et 2 O (100 mL). The organic layer was concentrated by MgSO 4 Dry, filter and concentrate the filtrate under reduced pressure. The residue was dry loaded onto silica gel and then purified by HPLC using DCM (CH 2 Cl 2 ) gradient (1:9 to 4:6) as eluent, purified by silica gel column chromatography (10 g Biotage HC column) to give the title compound (450 mg, 51%) as a viscous oil. Retention time 1.570 min; 1H NMR (400 MHz, CDCl 3 )δ5.10(1H,dd,J=4.0Hz and 2.8Hz),4.42(1H,dd,J=12.0Hz and 4.0Hz),4.35(1H,dd,J=11.6Hz and 2.8Hz).
[0336] Step 3: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-5,6,7,8-d 4 )-4,5-dihydro-1H-imidazole
[0337] In N 2 2,3-Dihydrobenzo[b][1,4]dioxin-2-carbonitrile-5,6,7,8-d 4 To a stirred solution of 144 mg, 0.87 mmol) in dry MeOH (3 mL) was added NaOMe (1.88 mg, 0.035 mmol) in one portion. The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and ethane-1,2-diamine (64 μL, 0.96 mmol) was added in one portion. After 5 minutes, HCl (1.25 M; 767 μL, 0.96 mmol) in MeOH was added dropwise. The mixture was allowed to warm to room temperature and stirred at room temperature overnight. The solvent was concentrated under reduced pressure and 2 M ammonia (CH 2 Cl 2 The residue was purified by silica gel column chromatography with 2% (1:9) as eluent to give the title compound (72 mg, 39%) as a solid. Retention time 0.994 min; C 11 H 8 D 4 N 2 O 2 m / z = [M + H] + Calculated value 209.1; Measured value 209.2; 1 H NMR (400 MHz, CDCl 3 )δ5.06(1H,br s),4.89(1H,dd,J=7.6Hz and 2.4Hz),4.54(1H,dd,J=11.6Hz and 2.8Hz),4.18(1H,dd,J=7.6Hz and 11.2Hz),4.10–3.25(4H,br m). By measuring 1 Integration of the residual aromatic protons in the H NMR determined that the deuterium incorporation of this compound was 96.3%.
[0338] Example 2: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-5,6,7,8-d4)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (Compound 52)
[0339]
[0340] In N 2 To a stirred solution of 5,6,7,8-tetradeutero-2,3-dihydro-1,4-benzodioxin-3-carbonitrile (139 mg, 0.84 mmol) in dry MeOH (3 mL) was added sodium methoxide (25.0 wt % solution in MeOH, 7.70 μL, 0.034 mmol) in one portion under an atmosphere and ice bath cooling (0-5 ° C). The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and 1,1,2,2-tetradeuteroethane-1,2-diamine (61.8 μL, 0.93 mmol) was added in one portion. After 5 minutes, HCl in MeOH (1.25 M in MeOH, 741 μL, 0.93 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight, then H 2 O (40 mL), the mixture was washed with 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with CHCl 3 (2×20 mL) extraction. The combined organic layers were concentrated under reduced pressure to obtain the title compound (155 mg, 77%) as a solid. Retention time 0.957 minutes; C 11 H 4 D 8 N 2 O 2 m / z = [M + H] + Calculated value 213.1; Measured value 213.2; 1 H NMR (400 MHz, CDCl 3 )δ5.03 (1H, br s), 4.89 (1H, dd, J=8.0 Hz and 2.8 Hz), 4.54 (1H, dd, J=11.6 Hz and 2.8 Hz), 4.18 (1H, dd, J=11.2 Hz and 7.6 Hz).
[0341] Example 3: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6-d)-4,5-dihydro-1H-imidazole (Compound 1)
[0342]
[0343] Step 1: 6-Bromo-2,3-dihydro-1,4-benzodioxin-2-carboxamide
[0344] To a stirred suspension of 6-bromo-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid (250 mg, 0.97 mmol) in toluene (5 mL) was added thionyl chloride (141 μL, 1.93 mmol) in one portion. The suspension was heated to 100 °C and stirred for 2 hours, then toluene was removed under reduced pressure. The residue was co-evaporated with toluene (2 x 10 mL) to remove excess thionyl chloride. The residue was suspended in 1,4-dioxane (5 mL) and this mixture was added dropwise over 5 minutes to a stirred 33-34% aqueous NH 3 The ice bath was removed and the mixture was warmed to room temperature and stirred for 30 minutes before H 2 O (40 mL). The precipitate that appeared was collected by filtration and air-dried at 40°C to give the title compound (224 mg, 89%) as a solid. Retention time 1.510 min; 1 H NMR (400 MHz, DMSO-d 6 )δ7.53(1H,br.s),7.48(1H,br.s),7.07(1H,d,J=2.4Hz),7.03(1H,dd,J=8 .4Hz, 2.4Hz), 6.92 (1H, d, J = 8.8Hz), 4.79–4.47 (1H, m), 4.36–4.24 (2H, m).
[0345] Step 2: 6-Bromo-2,3-dihydro-1,4-benzodioxine-2-carbonitrile
[0346] To a stirred suspension of 6-bromo-2,3-dihydro-1,4-benzodioxine-2-carboxamide (170 mg, 0.66 mmol) in DMF (4 mL) at room temperature was added 2,4,6-trichloro-1,3,5-triazine (46 mg, 0.26 mmol) in portions over 2 minutes. The mixture was stirred at room temperature for 18 hours, then another portion of 2,4,6-trichloro-1,3,5-triazine (46 mg, 0.26 mmol) was added in one portion and the mixture was stirred at room temperature overnight. This mixture was combined with a smaller validation batch (50 mg scale) and then poured into H 2 O (50 mL) and washed with Et 2 O (4 x 20 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by silica gel column chromatography (Biotage Isolera system; 5 g HC silica gel column) using a gradient of EtOAc in hexanes (1:9 to 4:6) as eluent to give the title compound (176 mg, 85%) as a solid. Retention time 1.171 min; 1 H NMR (400 MHz, CDCl3 )δ7.12(1H, J=2.0Hz),7.04(1H,dd,J=8.8Hz and 2.4Hz),6.84(1H,J=8.4Hz),5.13–5.09(1H,m),4.49–4.30(2H,m).
[0347] Step 3: 2-(6-Bromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole
[0348] In N 2 To a stirred solution of 6-bromo-2,3-dihydro-1,4-benzodioxine-2-carbonitrile (175 mg, 0.73 mmol) in dry MeOH (4 mL) was added NaOMe (25 wt% solution in MeOH, 6.67 μL, 0.029 mmol) in a single portion under an atmosphere and ice bath cooling (0-5°C). The mixture was warmed to room temperature and stirred for 6 hours, at which time TLC analysis (eluent 1:1 hexane-CH 2 Cl 2 ) indicated that almost all of the starting nitrile had been converted to the imidate. The mixture was cooled in an ice bath and ethane-1,2-diamine (53.5 μL, 0.80 mmol) was added in one portion. After 5 minutes, HCl in MeOH (1.25 M; 642 μL, 0.80 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight before the addition of HCl. 2 O (40 mL), the mixture was washed with 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with DCM (CH 2 Cl 2 The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate the filtrate under reduced pressure to give the title compound (169 mg, 81%) as a solid. Retention time 1.172 minutes; C 11 H 11 Bn 2 O 2 m / z = [M + H] + Calculated value 283.0; Measured value 283.0; 1 H NMR (400 MHz, CDCl 3)δ7.06(1H, d, J=2.0Hz),6.97(1H, dd, J=8.8Hz and 2.4Hz),6.78(1H, J=8.8Hz),5.29(1H, br s),4.85(1H, dd, J=7.6Hz and 2.4Hz),4.53(1H, dd, J=11.6Hz and 2.4Hz),4.22–4.13(1H, m),3.97–3.81(2H, br m),3.57–3.38(2H, br m).
[0349] Step 4: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6-d)-4,5-dihydro-1H-imidazole
[0350] 2-(6-Bromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole (135 mg, 0.48 mmol) and 10% Pd / C (45 mg, 0.042 mmol) were dissolved in MeOH-d 4 The mixture in 40 mL of 1% NH 2 O (3.5 mL) was stirred at room temperature under deuterium atmosphere (about 20 psi) for 2 hours. The reaction mixture was filtered to remove the Pd / C catalyst and combined with a validation batch (30 mg scale). The reaction mixture was added to water (40 mL) and washed with 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with CHCl 3 The combined organic layers were concentrated under reduced pressure and washed with water in MeOH / DCM (CH 2 Cl 2 2M NH in (1:9) 3 The crude residue was purified by silica gel column chromatography using 4-(4-(4-oxo-1-yl)-4-nitropropene as eluent to afford the title compound (60 mg, 50%) as a viscous oil. Retention time 0.959 min; C 11 H 11 DN 2 O 2 m / z = [M + H] + Calculated value 206.1; Measured value 206.2; 1 H NMR (400 MHz, CDCl 3 )δ6.99–6.86 (3H, m), 4.94 (0.65H, due to partial deuteration at this position, dd, J=7.2 Hz and 2.4 Hz), 4.58–4.51 (1H, m), 4.27–4.19 (1H, m), 3.69 (4H, s).
[0351] Example 4: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-7-d)-4,5-dihydro-1H-imidazole (Compound 2)
[0352]
[0353] Step 1: 7-Bromo-2,3-dihydro-1,4-benzodioxine-2-carbonitrile
[0354] 4-Bromobenzene-1,2-diol (1.0 g, 5.29 mmol) and K 2 CO 3 2-Chloroprop-2-enenitrile (463 mg, 5.29 mmol) was added in one portion to a solution of (1.46 g, 10.6 mmol) in acetone (20 mL). The mixture was heated to 85 °C under microwave irradiation (Biotage Initiator microwave oven) and stirred for 12 hours. The mixture was concentrated under reduced pressure and the residue was heated to 40 °C. 2 The organic layer was concentrated under reduced pressure and the residue was combined with the crude product from a verification batch (1 g scale) and then purified by HPLC using DCM (CH 2 Cl 2 ) / hexane (1:9 to 4:6 gradient) as eluent by silica gel column chromatography (Biotage Isolera system; 10 g HC silica gel column) to give the title compound (703 mg, 27%) as a solid. Retention time 1.711 minutes; 1 H NMR (400 MHz, CDCl 3 )δ7.12(1H,d,J=2.4Hz),7.10–7.01(1H,m),6.84(1H,d,J=8.8Hz),5.12–5.06(1H,m),4.42(1H,dd,J=11.6Hz and 3.6Hz), 4.39–4.30(1H,m).
[0355] Step 2: 2-(7-Bromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole
[0356] In N 2 To a stirred solution of 7-bromo-2,3-dihydro-1,4-benzodioxin-2-carbonitrile (505 mg, 2.10 mmol) in dry MeOH (10 mL) was added NaOMe (4.55 mg, 0.084 mmol) in one portion under an atmosphere and ice bath cooling (0-5 ° C). The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and ethane-1,2-diamine (0.155 mL, 2.31 mmol) was added in one portion. After 5 minutes, HCl in MeOH (1.25 M; 1.85 mL, 2.31 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight, then H2 O (100 mL), with 33-34% aqueous NH 3 The solution (10 mL) was basified and washed with DCM (CH 2 Cl 2 ) (3×40 mL). The organic layer was dried over Na 2 SO 4 , filtered, and the filtrate was concentrated under reduced pressure and combined with a validation batch (200 mg scale). 2 Cl 2 The crude residue was purified by silica gel column chromatography using 2M ammonia in HCl (1:9) as eluent to afford the title compound (331 mg, 39%) as a solid. Retention time 1.169 min; C 11 H 11 Bn 2 O 2 m / z = [M + H] + Calculated value 283.0; Measured value 283.0; 1 H NMR (400MHz, CD 3 OD) δ7.12 (1H, d, J = 2.4Hz), 6.97 (1H, dd, J = 8.8Hz and 2.4Hz), 6.80 (1H, d, J = 8. 4Hz), 4.92–4.86(1H,m), 4.45–4.38(1H,m), 4.20–4.12(1H,m), 3.63(4H,s).
[0357] Step 3: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-7-d)-4,5-dihydro-1H-imidazole
[0358] 2-(7-Bromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole (30 mg, 0.11 mmol) and 10% Pd / C (10 mg) were dissolved in MeOH-d 4 The mixture in 4% ethanol (0.75 mL) was stirred at room temperature under a deuterium atmosphere (about 20 psi) for 2 hours. The mixture was filtered to remove Pd / C and the filtrate was directly loaded into a column treated with MeOH / DCM (CH 2 Cl 2 2M NH in (1:9) 3 Wet the silica gel with MeOH / DCM (CH 2 Cl 2 2M NH in (1:9) 3 Purification by silica gel column chromatography using as eluent gave the desired product (18 mg, 82%) as a viscous oil. Retention time 0.986 min; C 11 H 11 DN2 O 2 m / z = [M + H] + Calculated value 206.0; Measured value 206.2; 1 H NMR (400MHz, CD 3 OD) δ 6.94 (1H, br s), 6.85 (2H, br s), 4.91–4.87 (1H, m, partially obscured by water peak), 4.46–4.38 (1H, m), 4.20–4.10 (1H, m), 3.64 (4H, s).
[0359] Example 5: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6,7-d2)-4,5-dihydro-1H-imidazole (Compound 3)
[0360]
[0361] Step 1: 6,7-Dibromo-2,3-dihydro-1,4-benzodioxin-2-carbonitrile
[0362] To a stirred solution of 4,5-dibromobenzene-1,2-diol (1.53 g, 5.71 mmol) in acetone (30 mL) was added 2-chloroprop-2-enenitrile (0.50 g, 5.71 mmol) in one portion. The mixture was heated to 50 °C and stirred overnight, then concentrated under reduced pressure and the residue was concentrated under H 2 The organic layer was concentrated under reduced pressure and washed with DCM (CH 2 Cl 2 The residue was purified by silica gel column chromatography (10 g Biotage HC column) using 2:4-(2:8 to 4:6) as eluent to give the title compound (1.06 g, 58%) as a solid. Retention time 1.765 min; C 9 H 5 Br 2 NO 2 m / z = [M + H] + Calculated value 317.8; Measured value 317.8; 1 H NMR (400 MHz, CDCl 3 )δ7.15–7.08 (2H, m), 5.24 (1H, dd, J = 3.6 Hz and 2.4 Hz), 4.56 (1H, dd, J = 12.0 Hz and 3.6 Hz), 4.43 (1H, dd, J = 12.0 Hz and 2.4 Hz)
[0363] Step 2: 2-(6,7-dibromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole
[0364] In N 2 To a stirred solution of 6,7-dibromo-2,3-dihydro-1,4-benzodioxin-2-carbonitrile (420 mg, 1.32 mmol) in dry MeOH (16 mL) was added sodium methoxide (25 wt% solution in MeOH, 12 μL, 0.053 mmol) in one portion under an atmosphere and ice bath cooling (0-5 °C). The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and ethane-1,2-diamine (96.7 μL, 1.45 mmol) was added in one portion. After 5 minutes, 1.25 M HCl (1.16 mL, 1.45 mmol) in MeOH was added dropwise. The mixture was allowed to warm to room temperature and stirred at room temperature overnight. The precipitate was isolated by filtration, washed with cold MeOH (1 mL) and air-dried to give the title compound (312 mg, 62%) as a solid. Retention time 1.213 minutes; C 11 H 10 Br 2 N 2 O 2 m / z = [M + H] + Calculated value: 362.9; Measured value: 362.8; 1 H NMR (400 MHz, DMSO-d 6 )δ7.14–7.08(2H,m),6.50(1H,br.s),5.03(1H,dd,J=6.4,2.4Hz),4.52(1H,dd,J=11.6,2.8Hz),4.34(1H,dd,J=11.6,6.4Hz), 3.80–3.20(4H,br.s).
[0365] Step 3: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6,7-d2)-4,5-dihydro-1H-imidazole
[0366] 2-(6,7-Dibromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole (303 mg, 0.84 mmol) and 10% Pd / C (79 mg, 0.74 mmol) were dissolved in MeOH-d 4 The stirred solution in (6 mL) was heated at room temperature, D 2 Stir under atmosphere (about 20 psi) for 24 hours. Filter the mixture and concentrate the filtrate under reduced pressure. Use MeOH / DCM (CH 2 Cl 2 2M NH in (5:95 to 15:85)3 The residue was purified by silica gel column chromatography as eluent to give the title compound (126 mg, 73%) as a viscous oil. Retention time 0.753 min; C 11 H 10 D 2 N 2 O 2 m / z = [M + H] + Calculated value 207.1; Measured value 207.2; 1 HNMR (400MHz, CD 3 OD) δ6.93–6.85(2H,m),5.42(1H,dd,J=5.6,2.4Hz), 4.47(1H,dd,J=12.0,2.8Hz), 4.38(1H,dd,J=12.0,5.6Hz), 4.00(4H,s).
[0367] Example 6: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6-d)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (Compound 49)
[0368]
[0369] Step 1: 2-(6-Bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0370] In N 2 To a stirred mixture of 6-bromo-2,3-dihydro-1,4-benzodioxin-2-carbonitrile (170 mg, 0.71 mmol) in dry MeOH (4 ml) was added sodium methoxide (25 wt % solution in MeOH, 6.5 μL, 0.028 mmol) in one portion under an atmosphere and ice bath cooling (0-5 ° C). The mixture was warmed to room temperature and stirred for 7 hours, then cooled in an ice bath and 1,1,2,2-tetradeuterated ethane-1,2-diamine (48.9 μL, 0.78 mmol) was added in one portion. After 5 minutes, hydrogen chloride (1.25 M in MeOH) (623 μL, 0.78 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight, then H 2 O (40 mL) and 33-34% aqueous NH 3 The solution (5 mL) was basified and the resulting precipitate was separated by filtration and air-dried to give the title compound (134 mg, 64%) as a solid. Retention time 2.850 min; C 11 H 7 D 4 Bn 2 O2 m / z = [M + H] + Calculated value 287.0; Measured value 287.0; 1 H NMR (400 MHz, CDCl 3 )δ7.06(1H,d,J=2.4Hz),6.97(1H,dd,J=8.4,2.4Hz),6.78(1H,J=8.4Hz),4.98(1H,br.s) ,4.85(1H,dd,J=7.6,2.4Hz), 4.53(1H,dd,J=11.6,2.8Hz), 4.17(1H,dd,J=11.6,8.0Hz).
[0371] Step 2: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6-d)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0372] 2-(6-bromo-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-(4,4,5,5- 2 H 4 )-1H-imidazole (130 mg, 0.45 mmol) and 10% Pd / C (42.7 mg, 0.04 mmol) in MeOH-d 4 The stirred mixture in (2.5 mL) was heated at room temperature. 2 Stir for 2 hours under a 20 psi atmosphere. The mixture was filtered and poured into H 2 O (40 mL) and 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with CHCl 3 The combined organic layers were concentrated under reduced pressure and purified by using MeOH / DCM (CH 2 Cl 2 2M NH in (1:9) 3 The crude residue was purified by silica gel column chromatography to give the title compound (78 mg, 82%) as a viscous oil. Retention time 0.779 min; C 11 H 7 D 5 N 2 O 2 m / z = [M + H] + Calculated value 210.1; Measured value 210.2; 1 H NMR (400 MHz, CDCl 3)δ7.00–6.84 (3H, m), 4.90 (0.57H, due to partial deuteration at this position, dd, J=8.0, 2.8 Hz), 4.57–4.50 (1H, m), 4.22–4.13 (1H, m).
[0373] Example 7: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-7-d)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (Compound 50)
[0374]
[0375] Step 1: 2-(7-Bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0376] In N 2 To a mixture of 7-bromo-2,3-dihydro-1,4-benzodioxin-2-carbonitrile (200 mg, 0.88 mmol) in dry MeOH (4 mL) was added sodium methoxide (25 wt%, 7.6 μl, 0.033 mmol) in a single portion under an atmosphere and ice bath cooling (0-5°C). The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and 1,1,2,2-tetradeuterated ethane-1,2-diamine (57.5 μL, 0.92 mmol) was added in a single portion. After 5 minutes, 1.25 M HCl (0.73 mL, 0.92 mmol) in MeOH was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight, then treated with H 2 O (40 mL) and diluted with 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with DCM (CH 2 Cl 2 The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate the filtrate under reduced pressure to obtain the title compound (210 mg, 87%) as a solid. Retention time 1.169 minutes; C 11 H 7 D 4 Bn 2 O 2 m / z = [M + H] + Calculated value 287.0; Measured value 287.0; 1 H NMR (400 MHz, DMSO-d 6)δ7.12–7.08(1H,m),7.05–6.98(1H,m),6.90–6.81(1H,m),4.92–4.86(1H,m),4.46–4.37(1H,m),4.26–4.15(1H,m).
[0377] Step 2: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-7-d)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0378] 2-(7-Bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (205 mg, 0.71 mmol) and 10% Pd / C (67 mg) were dissolved in MeOH-d 4 The mixture in (4 mL) was heated at room temperature, D 2 Stir for 2 hours under atmosphere (about 20 psi). The mixture was filtered and the filtrate was directly loaded into a column treated with MeOH / DCM (CH 2 Cl 2 2MNH in (1:9) 3 Wet the silica gel with MeOH / DCM (CH 2 Cl 2 2M NH in (1:9) 3 The mixture was purified by silica gel column chromatography using as eluent to give the title compound (86 mg, 57%) as a viscous oil. Retention time 0.981 min; C 11 H 7 D 5 N 2 O 2 m / z = [M + H] + Calculated value 210.1; Measured value 210.2; 1 H NMR (400 MHz, CDCl 3 )δ6.96–6.82 (3H, m), 5.02 (1H, br.s), 4.88 (0.62H, due to partial deuteration at this position, dd, J=8.0, 5.2Hz), 4.57–4.50 (1H, m), 4.21–4.11 (1H, m).
[0379] Example 8: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6,7-d2)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (Compound 51)
[0380]
[0381] Step 1: 2-(6,7-Dibromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0382] In N 2 To a stirred solution of 6,7-dibromo-2,3-dihydro-1,4-benzodioxin-3-carbonitrile (86 mg, 0.27 mmol) in dry MeOH (4 mL) was added sodium methoxide (25 wt % in MeOH, 2.5 μL, 0.011 mmol) under an atmosphere and ice / water bath cooling. The mixture was warmed to room temperature and stirred for 18 hours, then cooled in an ice bath and 1,1,2,2-tetradeuterated ethane-1,2-diamine (18.6 μL, 0.30 mmol) was added in one portion. After 5 minutes, 1.25 M HCl in MeOH (237 μL, 0.30 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred for 24 hours, then added to a 33-34% aqueous NH 3 The solution (5 mL) was added to ice water (30 mL). The mixture was stirred for 5 minutes and the precipitate that appeared was separated by filtration and air-dried to give the title compound (32 mg, 32%) as a solid. Retention time 1.192 minutes; C 11 H 6 Br 2 D 4 N 2 O 2 m / z = [M + H] + Calculated value 366.9; Measured value 366.9; 1 H NMR (400 MHz, DMSO-d 6 )δ7.17–7.08(2H,m),5.04(1H,dd,J=6.8,2.8Hz), 4.53(1H,dd,J=11.6,2.8Hz), 4.35(1H,dd,J=11.6,6.8Hz).
[0383] Step 2: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl-6,7-d2)-4,5-dihydro-1H-imidazole-4,4,5,5-d4
[0384] 2-(6,7-dibromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (30 mg, 0.082 mmol) and 10% Pd / C (15 mg, 0.014 mmol) were added to a mixture of MeOH-d 4 N-ethyl-N-isopropyl-propan-2-amine (28 mL, 0.16 mmol) was added to the stirred mixture in 4% paraformaldehyde (2.5 ml). The mixture was stirred at room temperature.2 The mixture was stirred under a 4% CO atmosphere (about 20 psi) for 24 h and then filtered through a pad of celite. The filtrate was washed with H 2 O (40 mL) and diluted with 33-34% aqueous NH 3 The solution (5 mL) was basified and washed with CHCl 3 (2×20 ml) extraction. The combined organic layers were concentrated under reduced pressure to give the title compound (11 mg, 63%) as a viscous oil. Retention time 0.935 minutes; C 11 H 6 D 6 N 2 O 2 m / z = [M + H] + Calculated value 211.1; Measured value 211.2; 1 H NMR (400 MHz, CDCl 3 )δ6.92–6.85(2H,m),5.02(1H,br.s),4.88(about 0.25H,dd,J=7.6,2.4Hz),4.58–4.49(1H,m),4.22–4.14(1H,m).
[0385] Note – LCMS and NMR showed C H About 75% of α is deuterated to the imidazoline ring.
[0386] Example 9: 2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-imidazole-4,4,5,5-d4 (Compound 64)
[0387]
[0388] In N 2 To a stirred mixture of 2,3-dihydro-1,4-benzodioxin-2-carbonitrile (120 mg, 0.75 mmol) in dry MeOH (2.5 mL) was added sodium methoxide (25 wt% in MeOH) (6.8 μL, 0.03 mmol) in one portion under an atmosphere and ice bath cooling (0-5°C). The mixture was warmed to room temperature and stirred for 6 hours, then cooled in an ice bath and 1,1,2,2-tetradeuterated ethane-1,2-diamine (51 μL, 0.82 mmol) was added in one portion. After 5 minutes, 1.25 M HCl in MeOH (655 μL, 0.82 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred overnight, then treated with H 2 O (50 mL) and diluted with 33-34% aqueous NH 3 The solution (3 mL) was basified and washed with DCM (CH 2 Cl 2The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (143 mg, 92%) as a solid. Retention time 0.982 minutes; C 11 H 8 D 4 N 2 O 2 m / z = [M + H] + Calculated value 209.1; Measured value 209.2; 1 H NMR (400 MHz, CDCl 3 )δ6.98–6.85(4H,m),5.03(1H,br.s),4.89(1H,dd,J=8.0,2.8Hz), 4.54(1H,dd,J=11.6,2.8Hz), 4.18(1H,dd,J=11.6,8.0Hz).
[0389] Example 10: Enantiomerically enriched compounds
[0390] Compounds of the present disclosure (e.g., compounds 1, 2, 3, 4, 49, 50, 51, 52, and 64) can be obtained as single enantiomers, for example, by resolution of the racemic deuterated compounds with (+)-tartaric acid or (-)-tartaric acid or by chiral HPLC (e.g., as shown in the table below).
[0391]
[0392]
[0393]
[0394] Biological Example 1: Pharmacokinetic Profile of Deuterated Compounds
[0395] Stability in microsomes can be assessed using the protocol described in WO 2020 / 132461, which is incorporated herein by reference in its entirety. Stability in microsomes was assessed using the protocol described below.
[0396] Evaluation of metabolic stability in human liver microsomes
[0397] Program Overview
[0398] Test compounds (1 μM) were incubated with pooled liver microsomes. Test compounds were incubated at 5 time points during the 45 minute assay and analyzed by LC-MS / MS.
[0399] Purpose
[0400] The stability of the test compounds in the presence of liver microsomes was determined.
[0401] Customer Request
[0402] Compound identifier, molecular weight and / or molecular formula.
[0403] • 50 μL of 10 mM test compound solution in DMSO for each species, each assay condition.
[0404] Experimental Procedure
[0405] Pooled liver microsomes were purchased from a reputable commercial supplier. The microsomes were stored at -80°C until use.
[0406] Microsomes (final protein concentration 0.5 mg / mL), 0.1 M phosphate buffer (pH 7.4) and test compounds (final substrate concentration 1 μM; final DMSO concentration 0.25%) were pre-incubated at 37°C, and NADPH (final concentration 1 mM) was then added to initiate the reaction. A negative cofactor control incubation was included for each compound tested, in which 0.1 M phosphate buffer (pH 7.4) was added instead of NADPH (without NADPH). Two control compounds were included for each category. All incubations were performed in single runs for each test compound.
[0407] Each compound was incubated for 0, 5, 15, 30 and 45 minutes. A control group (without NADPH) was incubated for 45 minutes only. The reaction was terminated by transferring the incubations to acetonitrile at a 1:3 ratio at the appropriate time points. The termination plate was centrifuged at 3,000 rpm for 20 minutes at 4°C to precipitate the protein.
[0408] Quantitative analysis
[0409] After protein precipitation, sample supernatants were pooled into cartridges of up to 4 compounds, internal standards were added and samples were analyzed using generic LCMS / MS conditions.
[0410] Optionally, if metabolite analysis is required after the stability assay, a second assay is performed in which the compound is incubated four times and the four resulting incubations are pooled to give a higher sample concentration for analysis. The time point at which 30-70% of the parent compound has been degraded is then investigated at 3 different levels of metabolite analysis and / or identification.
[0411] Data analysis
[0412] From the plot of ln peak area ratio (compound peak area / internal standard peak area) versus time, determine the slope of the line. Subsequently, calculate the half-life and intrinsic clearance using the following formula:
[0413] Elimination rate constant (k) = (- gradient)
[0414] Half-life (t1 / 2) (minutes) = 0.693 / k
[0415] Intrinsic clearance (CLint) (μL / min / mg protein) = (V x 0.693) / t1 / 2
[0416] Where V = incubation volume (μL) / microsomal protein (mg)
[0417] Relevant control compounds are evaluated to ensure that the intrinsic clearance values fall within the specified limits (if available). Any failures are rejected and the assay is repeated. The intrinsic clearance (CLint) and standard error (SE CLint), t1 / 2 and n (number of time points used to calculate CLint) of the test compound are returned.
[0418] In these experiments, increases in half-life values equal to or greater than 15% were considered significant differences, and significant differentiation was considered if the apparent intrinsic clearance ratio (deuterated compound / idazoxan) was >1.15 or <0.85.
[0419] An alternative is described in WO 2020 / 132461 (incorporated herein in its entirety by reference) and is briefly described below.
[0420] Microsomal assay: Human liver microsomes (20 mg / mL) were obtained from Xenotech, LLC (Lenexa, KS). β-Nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH), magnesium chloride (MgCl 2 ) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich.
[0421] Metabolic stability assay: A 7.5 mM stock solution of each compound or a pharmaceutically acceptable salt thereof was prepared in DMSO. The 7.5 mM stock solution was diluted to 12.5-50 μM in acetonitrile (ACN). 20 mg / mL human liver microsomes were diluted in 0.1 M potassium phosphate buffer (pH 7.4, containing 3 mM MgCl 2 ) was diluted to 0.625 mg / mL. The diluted microsomes were added to the wells of a 96-well deep-well polypropylene plate in triplicate. A 10 pL aliquot of the test compound (12.5-50 μM) was added to the microsomes and the mixture was preheated for 10 minutes. The reaction was initiated by adding a preheated NADPH solution. The final reaction volume was 0.5 mL and contained 4.0 mg / mL human liver microsomes, 0.25 μM test compound and 0.1 M potassium phosphate buffer (pH 7.4) and 3 mM MgCl 22mM NADPH in . The reaction mixture was incubated at 37°C and 50pL aliquots were taken out at 0, 5, 10, 20 and 30 minutes and added to a shallow well of a 96-well plate containing 50pL ice-cold ACN (acetonitrile) and an internal standard to stop the reaction. The plate was stored at 4°C for 20 minutes, and then 100pL of water was added to the wells of the plate, followed by centrifugation to precipitate the precipitated protein. The supernatant was transferred to another 96-well plate and the amount of the remaining parent compound was analyzed by LC-MS / MS using an Applied Bio-systems API 4000 mass spectrometer. The same procedure was followed for the non-deuterated counterpart and the positive control 7-ethoxycoumarin (1μM). The test was performed in triplicate.
[0422] Data analysis: The in vitro T values of the test compounds were calculated by the slope of the linear regression of the percentage of parent compound remaining (In) versus incubation time. 1 / 2 .
[0423] In vitro T 1 / 2 =0.693 / k
[0424] k = -[the slope of the linear regression of the percentage of parent compound remaining (In) versus incubation time]
[0425] Apparent intrinsic clearance was calculated using the following formula:
[0426] CL int (mL / min / kg) = (0.693 / in vitro T)(incubation volume / mg of microsomes)(45 mg of microsomes / gram of liver)(20 g of liver / kg of body weight)
[0427] Data analysis was performed using Microsoft Excel software.
[0428] Evaluation of metabolic stability in human liver microsomes - Results
[0429] Test compound concentration = 3 μM
[0430] Microsome concentration = 0.5 mg / mL
[0431] Time point = 0, 5, 15, 30, 45 minutes
[0432] Cofactor = NADPH
[0433] Final DMSO concentration = 0.25%
[0434] Control = 0 μM (blank); positive control compound with known activity
[0435] Analytical method = LC-MS / MS
[0436] Table 2. Metabolic stability of representative deuterated compounds in human liver microsomes.
[0437] Compound ID <![CDATA[CL int (μL / min / mg protein)]]> <![CDATA[t 1 / 2 (min)]]> n Compound 1 2.87 483 5 Compound 2 1.06 1310 5 Compound 3 2.23 622 5 Compound 4 2.59 536 5 Compound 49 1.49 932 5 Compound 50 0.0253 54800 5 Compound 51 1.68 825 5 Compound 52 2.98 465 5 Compound 64 2.91 477 5 Idazoxan 5.39 257 5 Dextromethorphan 48.1 28.8 5 Verapamil* 315 4.40 3 Diazepam 89.4 15.5 5 Diphenhydramine* 690 2.01 3
[0438] *30 and 45 minute time points were excluded because verapamil and diphenhydramine are metabolized very quickly and completely eliminated within 30 minutes. Therefore, measurements could not be performed at 30 and 45 minute time points.
[0439] According to the results in Table 2, compounds 1, 2, 3, 4, 49, 50, 51, 52 and 64 showed significant differences in in vitro clearance and half-life compared with idazoxan.
[0440] Biological Example 2: Oral Bioavailability in Rats
[0441] The pharmacokinetics of the test compounds were determined after a single intravenous or oral administration to rats. Pharmacokinetic (PK) studies were conducted on three male Sprague-Dawley (SD) rats after intravenous (IV) and oral (PO) administration of idazoxan or a deuterated idazoxan analog of the present disclosure at 1 mg / kg (IV) and 10 (PO) mg / kg doses. Test compounds or idazoxan were measured in plasma.
[0442] Rat strain
[0443] The rats used in these studies were provided by Charles River (Margate UK) and were specific pathogen free. The strain of rats was Sprague Dawley. Male rats weighed 175-225 g at receipt and required 5-7 days to acclimate.
[0444] Animal enclosure
[0445] Rats were group housed in individually ventilated sterile cages, with animals exposed to HEPA-filtered sterile air at all times. Animals had free access to food and water (sterile) and sterile poplar wood shavings bedding (at least once a week).
[0446] The room temperature was 22°C ± 1°C, the relative humidity was 60%, and the maximum background noise was 56 dB. The rats were exposed to a 12-h light / dark cycle.
[0447] treat
[0448] Each test compound was diluted in 10% v / v DMSO, 40% v / v PEG-400 and 50% v / v water. Test compounds were administered at a dose volume of 2 mL / kg (intravenous (IV)) and 5 mL / kg (PO) (oral administration route), respectively.
[0449] Single IV / PO Dose Pharmacokinetic Study in Rats
[0450] Each test compound was administered in a single IV bolus (via the lateral tail vein) or a single oral gavage in a cohort of 3 rats per route. After dosing, 100 μL whole blood samples (EDTA) were collected via the tail vein at the time points described in Table 3. The blood was centrifuged to separate the plasma. Approximately 40 μL of plasma was distributed in a 96-well plate per time point, per rat, and frozen until analysis. The plasma samples were subjected to bioanalysis.
[0451] Table 3: Pharmacokinetic characteristics of the test articles in rat plasma following single IV and oral administration
[0452]
[0453] Equivalence Case
[0454] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed within the scope of this application.
[0455] All patents, patent applications, and literature references cited herein are hereby expressly incorporated by reference.
Claims
1. A compound represented by formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
2. A compound represented by formula (II) or formula (III), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
3. A compound represented by formula (II-A) or formula (III-A): or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 3 , R 4 , R 4 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
4. The compound according to claim 1-3, wherein R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
5. The compound according to claim 1-4, wherein R 5 , R 6 , R 7 and R 8 At least two of them are deuterium.
6. The compound according to claim 1-4, wherein R 5 , R 6 , R 7 and R 8 At least three of them are deuterium.
7. The compound according to claim 1-4, wherein R 5 , R 6 , R 7 and R 8 It's all deuterium.
8. The compound according to claim 1-7, wherein R 1 , R 1 '、R 2 , R 2 'At least one of them is deuterium.
9. The compound according to claim 1-7, wherein R 1 , R 1 '、R 2 , R 2 At least two of the ' are deuterium.
10. The compound according to claim 1-7, wherein R 1 , R 1 '、R 2 , R 2 At least three of them are deuterium.
11. The compound according to claim 1-7, wherein R 1 , R 1 '、R 2 , R 2 'It's all deuterium.
12. The compound according to claim 1 or 2, wherein the compound is represented by formula (IA) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium, provided that R 1 , R 1 '、R 2 , R 2 '、R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
13. The compound according to claim 12, wherein R 1 , R 1 '、R 2 , R 2 'At least one of them is deuterium.
14. The compound according to claim 12 or 13, wherein R 1 and R 2 At least one of them is deuterium.
15. A compound according to any one of claims 12 to 14, wherein R 5 , R 6 , R 7 and R 8 At least one of them is deuterium.
16. A compound according to any one of claims 12 to 14, wherein R 6 and R 7 At least one of them is deuterium.
17. A compound as described in any one of claims 1-3 or 12, selected from the list consisting of: or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof.
18. A compound as described in any one of claims 1-3 or 12, selected from the list consisting of: or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof.
19. The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has a deuterium incorporation rate of at least 90%.
20. The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has a deuterium incorporation rate of at least 95%.
21. The compound of any one of the preceding claims, wherein each position specifically designated as deuterium has a deuterium incorporation rate of at least 97%.
22. A pharmaceutical composition comprising a compound according to any one of the preceding claims and a pharmaceutically acceptable excipient.
23. A method for treating or preventing a disease or disorder selected from the group consisting of psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorders, agitation, mood disorders, thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1-21 or a pharmaceutical composition according to claim 22.
24. Use of a compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a disease or disorder selected from the group consisting of psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, dementia with Lewy bodies, sleep disorders, agitation, mood disorders, thromboembolic disorders, autism, attention deficit hyperactivity disorder, and any combination thereof.
25. A kit comprising the compound of any one of claims 1-21 or the pharmaceutical composition of claim 22, and instructions for use thereof.
